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Abstract 
Introduction 
Platelet dysregulation in pre-diabetes plays a major role in the progression of prothrombotic and pro-
inflammatory conditions. Cardiovascular disease (CVD), which may occur at the pre-diabetic stage, are 
a common cause of morbidity in diabetic individuals. Despite treatment, people living with type 2 
diabetes are at an increased risk of developing CVD, which is attributed to increased platelet activation 
and platelet mediated cellular cross-talks. The aim of the study was to investigate platelet activation and 
function in prediabetes and to further evaluate the effects of oral glucose lowering and anti-
inflammatory therapy on platelet function a pre-diabetic state. 
Methodology 
Male mice were fed experimental diets, control low-fat diet (D12450J 10 kcal% fat) and a high-fat diet 
(HFD) (D12492, 60 kcal% fat) (Research Diets, NJ, USA). Platelet activation was determined by 
measuring the formation of spontaneous platelet-monocyte aggregate (PMA). The high-fat diet (HFD) 
fed mice were then randomized into 3 treatment groups; metformin (150mg/kg) and low-dose aspirin 
(3mg/kg) dual therapy; low-dose aspirin (3mg/kg); and clopidogrel (0.25mg/kg). The drugs were 
administered orally, once a day, every day for 3-weeks. We determined the pre-diabetic status of the 
mice by measuring their oral glucose tolerance and insulin levels. We further measured the 
haematological parameters. Platelet function and reactivity were determined by stimulating them with 
endogenous agonists, adenosine diphosphate (ADP), collagen and arachidonic acid, before and after 
treatment.  
Results 
Overall, there were no significant differences in the baseline characteristics such as body weights and 
insulin levels. However, after three weeks on the experimental diets, the high-fat diet (HFD) fed group 
exhibited delayed glucose clearance (p=0.0362). Baseline levels of platelet-monocyte aggregates were 
increased in the HFD group, p=0.0156. Post-stimulation with 4µM ADP and 20µM ADP, the HFD 
group expressed elevated levels of activated platelets, p<0.05. Metformin and low-dose aspirin-
treatment inhibited reversible platelet aggregation, p=0.0220. While, residual platelet activation was 
observed at a concentration of 20µM ADP, p=0.0535. In the low-dose aspirin group, there were no 
significant variations in platelet reactivity following stimulation with ADP, p>0.05. Clopidogrel 
treatment inhibited the platelet response to 20µM ADP (p=0.0313). 
Conclusion 
Despite anti-platelet treatment in pre-diabetes, platelets exhibit a varied response to endogenous 
agonists. Therapeutic targeting of these pathways may reduce the risk of thrombotic complications in 
xix 
 
pre-diabetes. We further highlight the potential synergistic benefit of using dual oral glucose lowering 
and antiplatelet treatment to minimize the high on-treatment platelet responses observed in pre-diabetes 
and T2DM.  
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Chapter 1. Introduction 
The metabolic syndrome, a cluster of insulin resistance, hyperinsulinaemia, dyslipidaemia, 
hypertension and obesity, is a common risk factor for both type 2 diabetes mellitus (T2DM) and 
cardiovascular disease (CVD) (1,2). In diabetics, the prevalence of masked hypertension may reach 
26.5%, which is associated with 31% higher odds of developing CVD in comparison with non-diabetics 
(3). Most individuals with T2DM are obese, and the global epidemic of obesity has played a major role 
in the dramatic increase in the incidence and prevalence of noncommunicable diseases in recent years 
(4). Low-grade chronic inflammation, which is characterised by abnormal adipokine and pro-
inflammatory signalling is one of the foremost factors identified in obese and T2DM individuals (5). 
For the latter, persistent levels of pro-inflammatory proteins can activate and upregulate the expression 
of tissue factor (TF), which is the initiator of the extrinsic coagulation cascade, on the surface of 
endothelial cells resulting in increased risk of atherothrombotic conditions (6). Activation of the 
extrinsic pathway results in the enzymatically active complex (FVIIa) which activates FIX and FX 
(serine proteases for the coagulation cascade). This ultimately leads to thrombin generation, as well as 
activation of fibrinogen and fibrin stabilizing factor FXIII in association with fibrin clot formation (7). 
Currently, there are limited therapies available to protect diabetic individuals at risk of developing the 
aforementioned complications. However, metformin, which is a commonly used glucose-lowering 
drug, is known to reduce platelet activation in newly diagnosed subjects with T2DM (8). Some of the 
mechanisms by which metformin induce its effects include enhancing intracellular antioxidants leading 
to the reduction of oxidative stress, as well as blocking plasminogen activator inhibitor-1 (PAI-1), 
thereby promoting fibrinolysis in diabetic individuals (1). Metformin also reduces the levels of FVII, 
fibrinogen and also shortens fibrinolysis times in non-diabetic individuals with a high hip-to-waist 
circumference ratio (1,9).  
Much evidence points to accelerated thrombogenesis and fibrinolysis in remaining the main underlying 
factors that contribute to the high risk of atherosclerosis in diabetic individuals (2). However, activated 
platelets also play a crucial role in the development of hypercoagulable states in T2DM (10,11). 
Elevated platelet reactivity in T2DM can be influenced by upregulated multiple signalling pathways 
(12). For example, increased platelet activation in high glucose concentrations can result in enhanced 
expression of P-selectin and drive fibrinogen binding leading to the formation of platelet-leukocyte 
aggregates (13). Similarly, activated monocytes have the potential to exacerbate a hypercoagulable state 
(14). Activated platelets are capable of binding to monocytes to form platelet-monocyte aggregates 
(PMAs), which are robust markers of exacerbated hypercoagulable state (11). Activated platelets and 
monocytes express surface TF which initiates the activation of the extrinsic coagulation cascade (15), 
contributing to the presence of hypercoagulable states in diabetic individuals (16,17). This phenomenon 
can be explained by the increased levels of TF expression on monocyte surfaces in T2DM (11).  
2 
 
Anti-coagulant drugs including salicylates display a high potential to reduce elevated platelet activation 
and function, leading to lower risk of cardiovascular events (10,18). However, it has also been noted 
that commonly used anticoagulant drugs may present limited efficacy in protecting against 
inflammatory induced complications. Notably, a recent study showed that aspirin monotherapy does 
not significantly reduce the incidence of CVD in T2DM individuals (19). Thus, in addition to 
investigating mechanisms involved in pro-inflammatory linked cardiovascular complications in 
diabetic individuals, novel therapeutics should also be assessed for the protective properties against 
such complications. To date, limited data is available on the role activated platelets and monocytes play 
in the development of CVD, hence this phenomenon needs to be evaluated. Therefore, in a series of co-
ordinated studies, this project investigated the effects of current T2DM therapy on the thrombotic 
profile in a pre-diabetic state. Mechanisms involved in disease development and progression, linking 
inflammation and pre-diabetes induced CVD complications were also assessed. Potential findings may 
prompt the inclusion of non-steroidal anti-inflammatory drugs to the current therapy which will also 
aid in reducing the prothrombotic state present in pre-diabetic individuals. It is of note that increasing 
research is targeting a pre-diabetic state to curb complications associated with diabetes-induced 
cardiovascular complications. 
1.1 Overall aim 
To investigate the effects of current T2DM therapy on the thrombotic profile in a pre-diabetic state. 
1.2. Objectives 
• To investigate platelet activation and function during the development of type 2 diabetes 
mellitus using a diet-induced model of pre-diabetes.  
• To determine the effects of endogenous agonists like arachidonic acid and adenosine 
diphosphate (ADP) in modulating platelet reactivity and monocyte function in pre-diabetic 
mice on anti-hyperglycaemic and anti-inflammatory treatment. 
• To investigate platelet reactivity in combined therapy of low dose aspirin and metformin-treated 
pre-diabetic mice. 
1.3. Research questions 
• How does pre-diabetes affect the reactivity and function of platelets during the development of 
T2DM? 
• What is the polarization status of monocytes in the pre-diabetic state? 
• Does aspirin as a monotherapy or as an add-on therapy to metformin inhibit platelet activation 
and function in pre-diabetic mice? 
• Does aspirin as a monotherapy show anti-inflammatory effects in pre-diabetic mice compared 
to add-on therapy when combined with metformin? 
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Chapter 2. Literature review 
2.1. Introduction 
Type 2 diabetes (T2DM) is diagnosed based on abnormally elevated fasting plasma glucose 
concentrations. It continues to be a global pandemic with over 415 million cases reported in 2015, and 
estimated to rise to 642 million by 2040 (1, 2). The prevalence of diabetes in adults was estimated to be 
8.8%, with 75% coming from low and middle-income countries such as those in Southern Africa (2). 
In 2013, Africa had a diabetes prevalence of 4.9%, and this figure is expected to have an increase of 
110% to 41.5 million cases by the year 2035 (3). In addition to a large number of undiagnosed cases, 
the rate of diabetes prevalence in developing countries has been hugely affected by increasing 
individuals classified as pre-diabetic (1,2). The state of pre-diabetes can be defined as impaired fasting 
glucose, impaired glucose tolerance or both (4), with these individuals at higher risk of developing 
T2DM (5). In 2010, an estimated 57 million people were diagnosed with pre-diabetes. In the United 
States of America, pre-diabetes contributed to 29.5% of the total diabetes prevalence. More than 470 
million people globally are expected to be suffering from this condition by 2030 (5, 6). Pre-diabetes is 
a high-risk state for diabetes with 5-10% conversion rate and a similar percentage reverting to 
normoglycaemia. It is associated with insulin resistance and beta β cell dysfunction which occur before 
noticeable changes in glucose levels (7). T2DM accounts for over 90% of all diabetes cases and is 
caused by the body’s inability to utilise insulin effectively (decreased insulin sensitivity) resulting in 
increased blood glucose levels (hyperglycaemia) accompanied by subsequent damage to body organs 
and vasculature (8). Indeed, almost four-fold of diabetic individuals die of cardiovascular complications 
(9). Therefore, this review discussed the relationship between T2DM and cardiovascular disease 
(CVD). It focused on the role hyperglycaemia has in the development of pro-inflammatory and 
ultimately hypercoagulable states associated with CVD. In addition, the review highlights the role of 
current anti-diabetic and anti-platelet treatment in curbing the susceptibility of vasculature in a diabetic 
state. To achieve this, a search strategy was developed using medical subheadings (MeSH) keywords 
type 2 diabetes mellitus, cardiovascular disease, inflammation, anti-diabetic treatment and anti-platelet 
treatment. MEDLINE (OVID interface, 2000 onwards), EMBASE (OVID interface, 2000 onwards) and 
Cochrane Central Register of Controlled Trials (Wiley interface, current issue) was used to search for 
published articles. A comprehensive approach was used to analyse extracted literature, discussing 
different components of risk factors and detrimental effects associated with inflammation and its role 
in T2DM induced cardiovascular complications. 
2.2. Type 2 diabetes and cardiovascular disease (CVD) 
T2DM individuals have a 2-4-fold increased risk of premature atherosclerotic vascular disease (ASVD) 
when compared to nondiabetic counterparts (10). These include; myocardial infarctions (MI), cerebral 
vascular disease and peripheral vascular diseases (10). T2DM is a combination of both pro-
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inflammatory and hypercoagulable states with alterations in the components of the Virchow’s triad (11). 
These altered components include endothelial damage or dysfunction, abnormal blood stasis, and 
altered haemostasis, platelets and fibrinolysis (Figure 2.1) (12). Alterations in any two of the Virchow’s 
triad components increases the risk of vascular thrombosis (13).  
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Illustration of the components of the Virchow’s triad that are altered in type 2 diabetes mellitus 
(T2DM). Vessel injury: this involves altered nitric oxide (NO) synthesis resulting in increased adhesion of 
peripheral blood mononuclear cells (PBMCs) to the endothelial surface of blood vessels. Endothelial cell 
dysfunction also results in altered NO synthesis as well as increased adhesion of PBMCs. Blood flow: stasis, 
varicose veins and valve stenosis result in alteration of the blood flow through slowing down or blockage caused 
by fibrin clot formation. Hypercoagulability: T2DM has been associated with increased levels of activated 
platelets as well as microparticles which contribute to the hypercoagulable state. Increased resistance to 
fibrinolysis has also been described in T2DM (11).  
2.3. Inflammation in obesity and type 2 diabetes 
Inflammation is the tissue’s response to injury and can be classified into cellular and humoral responses 
(14, 15). In humoral immune response, antibody-mediated immune response, triggers B-cells to become 
plasma cells which secrete antibodies. On the other hand, cellular immune response is primarily 
mediated by T-cells (T-helper and killer T-cells) that can activate other immune cells such as B-cells 
and natural killer cells (16). Acute inflammation is characterised by increased blood flow and 
accumulation of fluid, leukocytes and cytokines at the site of injury. It also includes the activation of 
endothelial cells (EC), tissue macrophages and platelets (15). Chronic inflammation is characterised by 
specific cellular and humoral immune cell responses at the site of injury and is defined according to the 
nature of inflammatory cells present (14, 15). Once the tissue injury has been resolved, acute 
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inflammatory cells are removed by lymphatics or apoptosis (17). Chronic inflammation results in 
monocyte chemotaxis to the site of inflammation where interferon γ (IFN γ) and monocyte 
chemoattractant protein-1 (MCP-1) activate macrophages. These macrophages are then retained at the 
site of inflammation by granulocyte macrophage colony stimulating factor (GM-CSF) and IFN γ where 
they increase levels of interleukin 1 (IL-1) and tumour necrosis factor (TNF) (14).  
Chronic inflammation, which is exacerbated by abdominal obesity, is associated with other metabolic 
syndrome complications such as insulin resistance (IR), T2DM and CVD (18). In obese individuals, 
adipocytes secrete adipokines that are involved in the initiation of inflammation (19). Acute 
hyperglycaemia induces an increase in the production of pro-inflammatory cytokines such as 
interleukin-6 (IL-6), tumour necrosis factor (TNF-α) and interleukin 18 (IL-18) (20). Diabetic 
individuals have increased plasma levels of inflammatory markers, including high-sensitivity C-
reactive protein, IL-6, TNF-α, soluble intercellular adhesion molecule (sICAM)-1, soluble vascular cell 
adhesion molecule (sVCAM)-1, soluble E-selectin, and matrix metalloprotease 2 and 9 (21). In 
addition, inflammatory conditions can trigger the production of TF in various cells, namely the ECs, 
vascular smooth muscle cells (VSMCs), monocytes and macrophages, granulocytes and platelets (22).  
2.4. Inflammatory mechanisms involved in diabetes-induced cardiovascular 
complications 
2.4.1. Tissue factor is implicated in pro-inflammatory induced injury 
Tissue factor is a membrane protein cofactor component of TF-factor VIIa complex enzyme (23, 24). 
It is associated with microvascular complications which are an indicator of endothelial dysfunction 
rather than pro-coagulant activity (25), and elevated levels of circulating TF in T2DM (10). The levels 
of circulating leukocyte and microparticle derived TF in blood have also been associated with the 
hypercoagulable state (10, 26). Although it remains unclear whether platelets are able to synthesize 
their own TF messenger RNA (mRNA), it has been previously suggested that TF can be expressed on 
the surface of platelets as a result of contamination from monocytes (27).  
There is still more research to be done to define hypercoagulable states with respect to coagulation, and 
various factors can initiate a pathological state leading to cardiovascular events. In this case, factor VIIa 
(activated coagulation factor VII) can also initiate the extrinsic coagulation cascade leading to fibrin 
deposition and platelet activation (28). When the endothelial surface is disrupted or activated, TF binds 
to FVIIa to form the complex which is responsible for the downstream activation of FIX and FX to 
FIXa and FXa, respectively (Figure 2.2). These two factors lead to the formation of prothrombinase 
complex and thrombin generation (10, 26).  
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Figure 2.2. Illustration of the effect of hyperglycaemic conditions on platelet CD40L, monocyte tissue factor (TF) 
mRNA and membrane surface protein. Based on a previous study, exposure to 24-hours of hyperglycaemic (20% 
glucose solution and glucose levels maintained at 11 mmol/l) conditions results in elevated levels of CD40L (a 
marker of platelet activation and immune modulation) and monocyte TF mRNA as well as the membrane surface 
protein. Increase in monocyte mRNA and protein leads to a hypercoagulable state (10). 
During T2DM disease progression, it is postulated that monocytes produce TF when they undergo 
phenotypic change as a result of altered transcription factors (NF-ĸB) leading to the formation of pro-
coagulant cells (27, 29). Lipopolysaccharide (LPS) induces the expression of TF on the surface of 
monocytes. It binds to LPS binding protein (LBP) to form an LPS/LBP complex which binds to CD14, 
activating signal transduction pathways and transcription factors to induce TF gene expression (30). 
Antigen derived T-helper cells, lymphokines, complement-derived anaphylatoxin C5a and antigen-
antibody complexes are also able to elicit TF expression on monocyte surface membrane (31). The 
underlying mechanisms of monocyte and neutrophil function in microvascular thrombosis remain 
unclear (22, 32). Nonetheless, the presence of leukocytes, monocytes and neutrophils, at the site of 
inflammation or vascular injury have been reported. Their interaction with platelets may directly 
contribute to increased fibrin generation by exposing TF, and indirectly by inactivating TF inhibitor 
(32). The tissue factor pathway inhibitor is a protein associated with the endothelial membrane and its 
increased levels indicate endothelial damage (33).  
2.4.2. Platelet structure and function and its role pro-inflammatory induced endothelial 
injury 
Platelets are very small enucleate cells with a diameter of 2-3µm formed by the fragmentation of much 
larger megakaryocytes (100µm) in the bone marrow (Figure 2.3) (34, 35). 
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Figure 2.3. Illustration of the differentiation of hematopoietic stem cells to megakaryocyte-erythroid progenitor 
cells. These cells differentiate into megakaryoblasts through interaction with thrombopoietin (TPO) and 
subsequent maturation into megakaryocytes. Megakaryocytes in the sinusoidal walls of the bone marrow shed 
large segments of cytoplasm into the bloodstream where the shear force of circulating blood fragments the 
segments into individual platelets (36). 
Platelets are largely inactive, they circulate close to the endothelium without any firm adhesion due to 
the anti-adhesive properties of intact endothelial cells. However, vascular damage leads to their 
activation and adhesion to the endothelial surface (37). Once activated, platelets bind to the exposed 
extracellular matrix (ECM) proteins such as collagen and von Willebrand factor (vWF) (35, 38). They 
express a repertoire of cell surface receptors on their phospholipid bilayer membrane, which are 
responsible for intracellular signalling. This includes CD36 (GPIV, a scavenger receptor), CD63 
(receptor for tissue inhibitor of metalloproteinase), CD9 (cell adhesion molecule), G-protein coupled 
receptors (GPCRs), glycoprotein IIb/IIIa and glucose transporter-3 (GLUT-3) (38). These trigger the 
release of α-granules that play a role in inflammation, coagulation and wound repair (Figure 2.4). 
GPCRs trigger the release of adenosine diphosphate (ADP) from dense granules which is an important 
agonist for platelet activation (38, 39). Low ATP/ADP ratios maintain enhanced glycolysis which arises 
due to suppressed mitochondrial metabolism, possibly via activation of 5' AMP-activated protein kinase 
(AMPK), the major regulator of energy metabolism in mammalian cells (40). On the other hand, high 
ATP/ADP ratios block glycolysis in aerobic non-proliferating cells (41). 
Platelet granules contain membrane as well as soluble receptors involved in haemostasis, inflammation 
and wound healing. Alpha (α) granules are spherical organelles which contain adhesion proteins 
fibrinogen, fibronectin, vWF, thrombospondin and vitronectin (36, 42). The granule’s exocytosis can 
be evaluated by the membrane expression of its contents such as P-selectin (CD62P), vWF and platelet 
factor-4 (PF4) (42). Dense granules are unique to platelets for containing mainly bioactive amines such 
as serotonin, histamine, adenosine diphosphate (ADP) and adenosine triphosphate (ATP) (36, 42). The 
exocytosis of these granules can also be evaluated by the release of its contents like ADP, ATP and 
serotonin (42). The exocytosis of both these granules is essential for platelet activation and function. 
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For example, upon activation of platelets, the P-selectin expressed from the α-granules acts as a point 
of adherence for leukocytes in the formation of platelet-leukocyte aggregates (43).  
 
 
Figure 2.4. Illustration of the structure of a resting platelet. There are four distinct zones; (1) The peripheral zone: 
which includes the outer membrane. In this zone, there are surface-connected channels known as the open 
canicular system (OCS) which allows for interaction between the platelet interior and plasma substances. (2) The 
sol-gel zone houses the platelet cytoskeleton which maintains the discoid shape. (3) The organelle zone contains 
the alpha (α) and dense granules, lysosomes and mitochondria. (4) The membrane zone contains the dense tubular 
system where calcium is concentrated and is responsible triggering for contractile events (35, 36). 
2.5. Adenosine diphosphate (ADP) receptors involved in platelet activation and 
function 
ADP is released from the dense granules of platelets during degranulation leading to irreversible 
aggregation (44, 45). Once released, it activates surrounding platelets through the P2Y1 and P2Y12 
receptors facilitating a positive feedback mechanism (46–49). P2Y1 is responsible for the mobilization 
of cytoplasmic calcium and mediating platelet shape modification following reversible aggregation. 
The P2Y12 receptor mediates irreversible platelet activation and aggregation without any modification 
(44). ADP release from the dense granules activates platelets and in-turn results in the release of α-
granule components. These components such as macrophage inflammatory protein 1 (MIP-1), normal 
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T-cell expressed, secreted (RANTES), interleukin-8 (IL-8), interleukin-β (IL-β), CD40 ligand (CD40L) 
and P-selectin are involved in recruitment and activation of other leukocytes (50). 
2.5.1. P2Y1 receptors 
The P2Y1 is a purinergic receptor and widely expressed in various cell lineages but is mostly expressed 
by platelets (51, 52). It is coupled with the Gαq proteins thereby triggering calcium release from internal 
stores in the dense tubular system leading to shape change and reversible aggregation (36, 44, 51). 
Transgenic P2Y1 deficient mice have been shown to display impaired platelet aggregation and resistance 
to ADP agonist-induced activation (44, 53), and the inhibition of P2Y1 receptor does not lead to platelet 
activation and aggregation (51). This is further demonstrated when P2Y1 deficient platelets exhibit no 
effect on ADP-dependant inhibition of adenylyl cyclase (39).  
2.5.2. P2Y12 receptor 
Similar to P2Y1, the P2Y12 receptor expression is not limited to platelets but is also present in the brain, 
glial cells and vascular smooth muscle (54). P2Y12 is a Gi-coupled (primarily Gαi2) receptor and plays 
a role in the activation of the fibrinogen receptor (integrin αIIbβ3), shear-induced platelet aggregation 
and thrombus formation (39, 55). Inhibition of this receptor by clopidogrel reduces levels of cyclic 
adenosine monophosphate (cAMP) suppressing the phosphorylation of vasodilator-stimulated 
phosphoprotein (VASP-P) by protein kinases (54, 56, 57). It has been shown that platelet reactivity 
measured in P2Y12 reactivity units (PRU) is significantly higher in diabetic individuals when compared 
to non-diabetic individuals (58). This may suggest the importance of the pathways involved in platelet 
function and their contribution to the hypercoagulable state in pre-diabetic and T2DM individuals. 
2.6. Platelet signalling pathways 
Platelet activation and signalling are classified into agonist interactions with their respective receptors 
and receptor-mediated early platelet activation pathways. The pathways can also be described by 
intermediate common signalling, integrin intervention inside-out signalling and outside in signalling 
(59). Platelets interact extracellularly and intracellularly through ligand binding using inside-out 
signalling. Once ligands bind to the integrins, they pass on information into the cell (outside-in 
signalling) (60). Some of the pathways that are implicated in the platelet-induced mechanism are briefly 
described below, namely the cyclooxygenase pathway, calcium signalling and protein kinase C 
signalling. 
2.6.1. Cyclooxygenase pathway 
Activated platelets release the enzyme cyclooxygenase (COX) which leads to oxidation of arachidonic 
acid and consequent synthesis of bioactive compounds such as thromboxane A2 (TxA2) (36, 61, 62). 
Arachidonic acid is metabolised into short-lived intermediates prostaglandin G2 and H2 which result in 
platelet activation and vasoconstriction (62). Cyclooxygenase 1 and COX 2 are the two main isoforms 
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which transform arachidonic acid into prostaglandin H2. This is then transformed into prostanoids, 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), prostaglandin I2 (PGI2) and TxA2 (63). Prostanoids 
are lipid mediators generated in response to the action of COX on arachidonic acid; they consist of 
thromboxanes, prostacyclins and prostaglandins. During low-grade inflammatory conditions such as 
pre-diabetes and T2DM, the biosynthesis of these prostanoids is elevated (64). Prostaglandin I2 and 
TxA2 are synthesised by COX-1 and COX-2 respectively and play a major role in the physiology and 
dysregulation of the function of blood vessels (63).  
2.6.2. Calcium signalling 
Cytosolic calcium plays a crucial role in platelet activation. Its elevation may be induced by intracellular 
store release of inositol-1,4,5-trisphosphate (IP3) receptor, or extracellularly by its entry through the 
plasma membrane by 1,2 diacyl-glycerol (DAG) (59, 65). In T2DM, intracellular calcium 
concentrations are elevated in resting platelets (66). Elevation of calcium activates the actin-myosin 
interaction which results in cytoskeleton reorganisation and ultimately platelet shape change (59, 65). 
Activation of the αIIbβ3 integrin is also attributed to elevated calcium levels, and this results in platelet 
degranulation, enhanced thromboxane production and aggregation (59, 65, 67). Additional effects of 
elevated calcium levels include activation of the protein kinase C (PKC), calmodulin and NO synthesis 
(59). 
2.6.3. Protein kinase C 
Protein kinase C (PKC) is involved in platelet granule secretion as well as aggregation which can be 
directly activated by arachidonic acid and DAG (68, 69). Together with increased intracellular calcium, 
prolonged PKC activation results in irreversible platelet aggregation (69). A study using a PKC inhibitor 
resulted in inhibited dense granule secretion thereby blocking aggregation and αIIbβ3 activation in 
platelets (61). In hyperglycaemic conditions, there is increased membrane-bound PKC in vivo and DAG 
levels are chronically elevated resulting in its activation (70, 71).  
Endogenous agonists such as ADP, arachidonic acid and collagen may contribute to the development 
of atherosclerosis. Adenosine diphosphate activates the P2Y pathway, consequently leading to platelet 
activation, shape change and aggregation (44). Whereas collagen is involved in initiating the intrinsic 
clotting cascade and has been shown to increase transforming growth factor (TGF-β1) and platelet-
derived growth factor (PDGF) (72). Platelet aggregation can be induced by collagen acting on 
glycoprotein VI/Fc receptor γ chain complex thereby activating enzymes Src and Syk family tyrosine 
kinases. These prompt signalling of the phosphatidylinositol 3-kinase (PI3K) which leads to activation 
of the fibrinogen receptor αIIbβ3 and therefore platelet aggregation (73). PI3K regulates cell survival 
and insulin signalling, and its dysregulation can initiate platelet aggregation (74). Aspirin inhibits the 
COX-1 and COX-2 pathways thereby attenuating the production of TxA2 (50), a mediator of platelet 
activation that can be upregulated in diabetes by the oxidation of arachidonic acid (75, 76).  
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Arachidonic acid causes an increase in platelet calcium levels in a positive feedback process that 
promotes its release from intracellular stores and microsomes (68). Current anti-diabetic drugs 
biguanides, such as metformin, can present anti-atherogenic and cardioprotective effects as shown by 
their ability to decrease platelet volume (77, 78). However, the mechanism by which this is achieved is 
not completely understood, with one study citing their ability to lower the mean platelet volume (MPV) 
in T2DM, as a potential mechanism (79). The use of metformin improves glycaemic control in T2DM 
individuals and decreases levels of markers of active coagulation such as platelet factor-4, thrombin 
and d-dimers (80, 81). Anti-platelet drugs such as aspirin and clopidogrel, have since been introduced 
to T2DM therapy to improve the risk of atherosclerosis by reducing plasma cytokines, C-reactive 
protein levels and intima-media thickness (82).  
2.7. Platelet function in type 2 diabetes 
Platelet dysregulation is common in T2DM, as platelets exhibit increased activation, adhesion and 
aggregation during this state (83). Diabetic individuals already display increased soluble form of P-
selectin (sP-selectin) found in plasma, when compared to non-diabetic controls (84). Hyperglycaemic 
conditions increase levels of ADP and thrombin receptor activating peptide (TRAP) induced platelet P-
selectin expression. In human blood incubated with high glucose concentrations, TRAP stimulation also 
increased fibrinogen binding and platelet-leukocyte aggregates (PLA) (70). Mean platelet volume has 
been used as a marker for platelet activation and its levels are significantly higher in T2DM that 
decreased after improved glycaemic control (79). High-fat diet (60% beef lard) induced diabetic 
C57BL/6J mice have been shown not to exhibit hyperaggregability or hypercoagulability (85). In this 
study, authors found no differences in P-selectin and CD61 (IIIa portion of the integrin GPIIb/IIIa) 
between the diabetic and non-diabetic control mice (85). These results highlight the need for more 
studies to confirm if high fat diet fed mouse is an appropriate model to investigate platelet function and 
aggregation in obesity and T2DM. 
2.8. Glucose-lowering drugs and platelet function 
Metformin is a glucose lowering drug that is widely used as the first line of therapy for T2DM 
individuals. The drug lowers blood glucose levels by improving insulin sensitivity and suppressing 
hepatic gluconeogenesis (86). The mode of action of metformin is still poorly understood; however, the 
improvement in insulin sensitivity is mediated by the post-receptor signalling modification in the insulin 
pathway (87–89). In addition, metformin can reduce platelet activation and oxidative stress by 
preserving intracellular anti-oxidant function in T2DM (90). This biguanide can also enhance insulin 
hepatic sensitivity which results in the reduction of gluconeogenesis and glycogenolysis, contributing 
to lower plasma glucose levels through the modulation of AMPK (89). Metformin induces the 
upregulation of GLUT1 and GLUT4 transporters in skeletal muscle and adipocytes leading to increased 
glucose uptake (89). The use of metformin has been tested in a combination therapy with anti-diabetic 
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add-ons of sulfonylureas and thiazolidinediones like glipizide and pioglitazone, respectively. 
Pioglitazone greatly reduced procaspase activating compound (PAC-1) binding, P-selectin expression 
and ADP induced aggregation as compared to glipizide (91). However, glipizide as an add-on therapy 
to metformin did have a better anti-glycaemic effect that pioglitazone (91). Anti-platelet drugs have 
also been introduced in addition to the anti-diabetic drugs as dual therapy in order to curb the increased 
hypercoagulable state associated with diabetics. 
Acetylsalicylic acid (ASA) is a non-steroidal anti-inflammatory drug used in low doses as anti-platelet 
treatment. For instance, aspirin acetylates COX-1 in the serine-530 position preventing arachidonic 
acid-induced inflammation by binding to the active site of the enzyme (Figure 2.5) (81). The Japanese 
primary prevention of atherosclerosis with aspirin for diabetes (JPAD) study showed no differences in 
the risk of CVD between aspirin at 100mg and placebo over a median follow up of 10.3 years (92). The 
study only investigated primary end-points such as coronary artery events, cerebrovascular events and 
vascular events (92). Platelets from diabetic individuals remain reactive in spite of anti-platelet 
treatment such as aspirin and clopidogrel, with 10-40% showing high residual platelet reactivity (57, 
93). 
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Figure 2.5. Illustration of pathways involved in platelet activation and the cyclooxygenase (COX) inhibitory role 
of aspirin. Plaque rupture and coagulation released mediators, collagen, von Willebrand factor (vWF) and 
thrombin bind to their respective receptors on the membrane surface of platelets such as glycoprotein VI (GPVI), 
glycoprotein Ib-IX-V (GPIb-IX-V), protease activated receptors (PAR) leading to the activation of platelets. This 
process subsequently leads to the activation of the integrin glycoprotein IIb-IIIa (GPIIb-IIIa), a known a receptor 
for fibrinogen binding and ultimately platelet aggregation. Activation of platelets also results in granule exocytosis 
and the increase in ADP agonist. The COX enzyme is also released post platelet activation and increases the 
synthesis of TxA2 which binds to its receptor thromboxane receptor (TP). Aspirin can inhibit the synthesis of 
prostanoid TxA2 and its receptor TP leading to the inhibition of platelet activation. The figure was adapted from 
a previous publication (94). 
Diabetic individuals taking aspirin at 100mg/daily and clopidogrel at 75mg/daily also showed high rates 
of periprocedural myocardial infarction compared to non-diabetic individuals (58). Similar results of 
persistently increased platelet reactivity in T2DM despite dual anti-platelet therapy of 85mg aspirin and 
150mg clopidogrel daily dose have also been reported (95). Some of the reasons attributed to the lack 
of response to anti-platelet treatments include insulin resistance, poor glycaemic control and enhanced 
inflammatory status (58). Insulin is assumed to play an anti-aggregational role in platelet activation 
through nitric oxide synthase and nitric oxide-dependent mechanisms which are dysregulated in a 
diabetic state (96). Suggesting more research is necessary to identify therapies that can target diverse 
mechanism involved in diabetes-induced vascular complications.  
2.9. Concluding remarks 
Diabetic patients present with multiple risk factors that make them susceptible to cardiovascular 
complications. Although pathophysiological mechanisms explaining deteriorated vascular function in 
a diabetic state are multifactorial, inflammation is among the leading features being investigated for its 
involvement during this process. Chronic low-grade inflammation, which is a major characteristic 
feature of T2DM, is associated with an increase in immature reticulated large platelets. These platelets 
are hyperreactive and less responsive to prominent platelet inhibition drugs like aspirin and clopidogrel 
(57, 58). The use of low dose aspirin was recommended in the early 2000s for diabetic individuals with 
CVD risk factors (97), based on positive results from studies on hypertension individuals, and for 
prevention after myocardial infarction (92, 98). However, from the various studies, platelets from 
diabetic individuals are still hyperreactive regardless of available treatment strategies. Diabetic 
individuals also experience CVD events despite anti-platelet treatment which prompts further studies 
into the mechanisms involved in the progression of these events. Most studies have been done on 
diabetic individuals who may already have developed adverse CVD complications. Studies are needed 
which will investigate the effects of anti-glycaemic and anti-platelet treatment at early stages in the 
development of T2DM such as in pre-diabetes. 
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3. Abstract 
Introduction 
The formation of platelet-monocyte aggregates (PMA) is a physiological feature which mediates the 
pro-inflammatory role of platelets. Elevated PMAs in pre-diabetes may result in the development of 
atherosclerosis. The aim of this study was to evaluate PMA formation in a pre-diabetes using a high-fat 
diet mouse model, providing evidence of a link between inflammation and the hypercoagulable state in 
pre-diabetes. 
Methods 
Whole blood was collected from two animal groups on low fat (control group) and high-fat diet (pre-
diabetic group). The glucose tolerance was determined using the oral glucose tolerance test and insulin 
measurement was done using the enzyme linked immunoassay (ELISA) technique. Baseline 
haematological parameters were also measured using the haemocytometer. PMAs were determined 
using whole blood flow cytometry. To determine the level of PMA formation, blood from mice was 
stained with an antibody cocktail containing CD45-BV500, CD14-PE and CD41-FITC antibodies.  
Results 
The mice had comparable body weights and insulin levels, however, the high-fat diet fed mice 
demonstrated delayed glucose clearance, indicating that these mice were pre-diabetic. Baseline PMA 
levels were elevated in the pre-diabetic group when compared to the controls. In addition, stimulation 
with the adenosine diphosphate (ADP) agonist also significantly increased the level of platelet-
monocyte aggregates in the non-diabetic control mice however these remained comparable in the pre-
diabetic mice. Baseline levels of monocytes, measured using the CD14 monocyte marker, were 
significantly decreased in the pre-diabetes. 
Conclusions 
In pre-diabetes, platelets readily interact with circulating monocytes and form PMAs which are early 
markers for atherosclerosis. For the present study, the decrease in CD14 monocyte marker, indicated a 
shift in the monocyte phenotype to the pro-inflammatory form CD14++, further providing a possible 
link of the pro-thrombotic and pro-inflammatory role of platelets in pre-diabetes. 
Keywords: flow cytometry; platelet-monocyte aggregates; pre-diabetes; pro-inflammation 
3.1. Introduction 
Chronic platelet activation has been associated with a sustained pro-inflammatory response and an 
increased risk of cardiovascular complications (1). Monocytes, via the surface membrane P-selectin 
glycoprotein ligand-1 (PSGL-1), bind to P-selectin expressed on the activated endothelial surface 
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mediated interaction (2). This represents the early events in the pathophysiological mechanisms leading 
to atherosclerosis in type 2 diabetes mellitus (T2DM) (3). In a similar manner, activated platelets are 
able to bind circulating peripheral blood leucocytes via P-selectin and PSGL-1 interactions, forming 
platelet-leukocyte aggregates (PLAs) (4,5). The binding of P-selectin to its counter-receptor PGSL1 
induces leukocyte tethering and firm adhesion of monocytes to the endothelium (6,7). As a result of the 
receptor-ligand binding, leukocytes are activated through the translocation of nuclear factor ĸB (NF-
ĸB), an important transcriptional factor that is responsible for pro-inflammatory molecule synthesis (7).  
Activation of the NF-ĸB pathway, in addition to increasing superoxide anion production, promotes 
accelerated levels of monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor-α (TNF-α), 
interleukin-8 (IL-8), IL-1β and cyclooxygenase-2 (COX-2) (5). Elevated expression of these pro-
inflammatory markers is concomitant with the formation of monocyte aggregates (PMA) (8). Previous 
studies have shown that platelets preferentially bind to monocytes, thus PMAs are regarded as stable 
markers of platelet activation (3,5,9). These interactions provide a link between the inflammatory and 
thrombotic responses involved in conditions such as T2DM where elevated levels of PMAs have been 
reported (10–12). The aim of this study was to evaluate PMA formation in a pre-diabetic mouse model, 
providing evidence of a link in the inflammatory status of diabetes with hypercoagulable status. 
Investigating a pre-diabetic state could identify essential pathophysiological mechanisms that are 
involved in early-stage development of T2DM. 
3.2. Methodology 
3.2.1. Study design 
Five-week-old C57BL/6 male mice were housed, individually in a cage, at the University of KwaZulu-
Natal (UKZN) biomedical research unit (BRU). Animals were handled according to the principles of 
laboratory Animal Care of the National Society of Medical Research and the National Institutes of 
Animal Care and Use of Laboratory Animals of the National Academy of Sciences (National Institute 
of Health publication 80-23, revised 1978). Ethical clearance was granted by the UKZN animal research 
ethics committee (AREC), ethics registration number AREC/086/016. Animals were allowed to 
acclimatize for a week before being fed on the experimental diets, control low-fat diet (n=8) (D12450J 
10 kcal% fat) and a high-fat diet (HFD) (n=22) (D12492, 60 kcal% fat) (Research Diets, NJ, USA). All 
mice had free access to water and food ad libitium. The animals were regularly monitored while the 
cages were cleaned once a week, to ensure a clean environment for the mice. 
3.2.2. Oral glucose tolerance tests 
Oral glucose tolerance tests were performed as previously described (13). In brief, after an 8 hour fast, 
2g/kg of glucose was administered using oral gavage technique. Blood glucose levels were then 
measured at different time intervals (30, 60, 120 minutes) using the Accu-Chek active blood glucometer 
(Roche, Basel, Switzerland).  
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3.2.3. Blood collection for haematology characteristics and flow cytometry analysis 
After 3 weeks on an HFD or control diet, 200µl of venous blood was collected using the tail bleeding 
method and the mice were terminated using inhalation of halothen. Venous blood was collected into 
3.2% citrate coated microtainer tubes (Sigma Aldrich, St Louis, Missouri, USA).  
3.2.4. Measurement of haematological parameters 
The Beckman Coulter Ac T diffTM analyser (Beckman Coulter, Brea, CA, USA.) was used to measure 
the baseline haematological parameters such as red blood cell count, white cell count, platelet count, 
haematocrit, mean cell volume and plateletcrit as per manufacturer’s protocol.  
3.2.5. Instrument set-up and optimization 
The BD FACSCanto II flow cytometer (BD Bioscience, NJ, USA) was used and the cytometer set-up 
and tracking (CST) beads (BD Bioscience, NJ, USA) were used to perform internal quality control (QC) 
as per manufacturer’s protocol. To compute and compensate for spectral overlap the BD ™ Compbead 
compensation particles (BD Bioscience, NJ, USA) were used. In addition, SPHERO ™ 6-peak Rainbow 
calibration particles (BD Bioscience, NJ, USA) were used daily as QC for the median fluorescence 
intensity (MFI).  
3.2.6. Measurement of baseline platelet-monocyte aggregates (PMA) 
The measurement of baseline (unstimulated) PMA levels was performed within 30 min blood 
collection. Briefly, 25µl of the blood was stained with 2.5µl (ratio 1:10) of the anti-mouse monoclonal 
antibody cocktail containing CD14-PE (clone: rmC5-3) (monocyte marker), CD41-FITC (clone: 
MWReg30) (platelet marker) and CD45-BV510 (clone: 30-F11) (leukocyte marker) for 10 minutes in 
the dark at room temperature. These samples were fixed using 25µl of thrombofix (Beckman Coulter, 
Brea, CA, USA) prior to red blood cell lysis. The samples were then lysed with 350µl FACSLyse lysis 
buffer (BD Bioscience, NJ, USA) for 15minutes in the dark at room temperature. This was then analysed 
on the BD FACSCanto II flow cytometer (BD Bioscience, NJ, USA).  
3.2.7. Measurement of PMA post stimulation with ADP 
To investigate the role of agonist-activated platelets in the formation of PMAs in hyperglycemic 
conditions, ADP was used to stimulate platelets and PMA levels were determined by flow cytometry. 
Briefly, 25µl of the citrated blood was incubated with 10µl (20µM) ADP for 15 minutes and then fixed 
with 25µl of thrombofix (Beckman Coulter, Brea, CA, USA). The sample was then stained with 2.5µl 
(ratio 1:10) of anti-mouse monoclonal antibody cocktail containing CD14-PE PE (clone: rmC5-3), 
CD41-FITC (clone: MWReg30) and CD45-BV510 (clone: 30-F11) (BD Bioscience, NJ, USA) and 
incubated for 10 minutes, at room temperature in the dark. The analysis was then done on the BD 
FACSCanto II flow cytometer (BD Bioscience, NJ, USA). 
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3.2.8. Gating strategy 
The pan-leukocyte marker (CD45) was used to identify leukocyte populations. The specific monocyte 
specific marker (CD14) was used to identify monocytes. In addition, CD41 was used to identify platelets 
bound monocytes and enumerate PMAs (Figure 3.1).  
 
Figure 3.1. Gating strategy for the analysis for platelet-monocyte aggregates (PMAs). (a) The pan-leukocyte 
marker CD45 that was used to identify leukocytes. The primary gate on the monocyte was determined using the 
side scatter properties which are higher compared to other leukocytes. (b) An unstained sample was used to set 
the negative population for autofluorescence and to set the gate to determine the quantitative (%CD14+) and 
qualitative level of monocytes (CD14+ MFI). (c) To determine the level of PMAs formed, the level of platelet-
bound monocytes was measured based on the (CD14+) monocyte population in (b). The quantitative (%CD41+) 
and qualitative (CD41+ MFI) expressions were determined based on the unstained sample as a negative control. 
PMA: platelet-monocyte aggregate; HFD: high-fat diet; MFI: median fluorescence intensity. 
3.2.9. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San Diego, California, 
USA). Non-parametric and parametric data were analysed using the Mann-Whitney test and unpaired 
t-test respectively. Non-parametric data were reported as the median IQR. Parametric data were 
reported as the mean ± standard deviation (SD). Statistical significance was defined as a p-value <0.05. 
3.3. Results 
3.3.1. Baseline characteristics 
Baseline characteristics of the control and experimental group are shown in Table 3.1. There were no 
significant differences in the baseline characteristics such as body weights or insulin levels, well as 
the white cell count, platelet count and monocyte count between the control group (n=8) and HFD 
group (n=22). However, these markers such as red blood cell count (p=0.0178), haematocrit 
(p=0.0433) and mean cell volume (p=0.0025) showed a significant difference when the HFD group 
was compared to the controls (Table 3.1). The oral glucose tolerance test (OGTT) showed that the 
HFD group had a higher postprandial blood glucose levels compared to the control group. This was 
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also illustrated by the higher area under the curve (AUC) observed in the HFD group indicating 
delayed blood glucose clearance in the HFD pre-diabetic group (p= 0.0091) (table 3.1). There were no 
differences in the insulin levels (0.2667) and body weights between the treatment groups (p=0.1749). 
Table 3.1. Baseline characteristics. 
Parameter Control (n=8) High-fat diet (n=22)  p-value 
Weight (g) 24.33[23.11- 26.83] 23.54[22.83- 24.49] 0.1749 
Insulin (µIU/ml) 16.16[15.43- 22.71] 19.69[17.04- 24.51] 0.2667 
OGTT (AUC) 852.0[717.0 - 918.0] 1068[1003 - 1095] 0.0091 
White cell count 
(103/µl) 
5.35[3.68- 9.00] 7.50[4.80- 8.40] 0.4699 
Red blood cell count 
(106/µl) 
7.17[7.04- 7.69] 6.910[5.53- 7.17] 0.0178 
Haemoglobin (g/dL) 25.85[20.00- 29.23] 22.40[16.75- 25.00] 0.6683 
Haematocrit (%)  31.10[30.05- 33.30] 29.00[23.00- 31.40] 0.0433 
Mean cell volume 
(fL) 
43.00[43.00- 43.75] 42.00[41.00- 44.00] 0.0025 
Platelet count 
(103/µL) 
782.9± 206.4 697.2± 151.1 0.5789 
Mean platelet 
volume (fL) 
5.30[5.03- 5.50] 5.20[5.10- 5.40] 0.6957 
Neutrophil count 
(%) 
7.75[7.00- 9.48] 8.000[6.90- 9.30] 0.9640 
Lymphocyte count 
(%) 
89.85[88.15- 90.73] 89.20[87.80- 90.50] 0.5271 
Monocyte count (%) 1.96± 0.24 2.05± 0.56 0.6840 
Basophil (%) 0.25[0.13- 0.50] 0.2000[0.10- 0.80] 0.7997 
Data presented as mean ±SD and median (IQR); p<0.05 represented in boldface. 
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3.3.2. Baseline levels of monocytes and platelet-monocyte aggregates 
The levels of monocytes were determined by measuring the levels of CD14 expression from each 
sample. The HFD 25.93±12.17 showed lower quantitative levels of monocyte (%CD14) compared to 
the control group 42.98±16.34, p=0.0093. In contrast, the qualitative median fluorescence intensity 
(MFI) was elevated in the HFD group 14.18±18.80 compared to the control group 5.66±0.51, p=0.0078 
(Table 3.2, Figure 3.2).  
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Figure 3.2. Monocyte and platelet-monocyte aggregate levels between the control group (n=8) and the high-fat 
diet (HFD) group (n=22). (a) Monocyte levels (%CD14) were significantly lower in the HFD group compared to 
the control group at baseline, p=0.0259. (b) The qualitative measurement (CD14 MFI) however was increased in 
the HFD compared to the control group, p=0.0078. PMAs were determined by the level of platelet-bound 
monocytes. (c) The HFD group had higher levels of PMA compared to the control group at baseline measurement, 
p=0.0156. (d) Similarly, the qualitative measurement (CD41 MFI) was increased in the HFD compared to the 
control group, p=0.0078. PMA: platelet-monocyte aggregate; HFD: high-fat diet; MFI: median fluorescence 
intensity.  
Baseline levels of platelet-monocyte aggregates (%CD41) were increased in the HFD group 
14.55±13.66 compared to the control group 9.28±4.05, p=0.0156. The qualitative analysis measured 
using the median fluorescence intensity (MFI), also showed increased levels in the HFD group 
28.45±34.13 compare to the control group 14.19±10.64, p=0.0078 (Table 3.2, Figure 3.2). 
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Table 3.2. Baseline platelet monocyte aggregate (PMA) levels. 
 Control (n=8) High-fat diet (n=22) p-value 
%CD14 42.98±16.34 25.93±12.17 0.0093 
CD14 MFI 5.66±0.51 14.18±18.80 0.0078 
%CD41 9.28±4.045 14.55±13.66 0.0156 
CD41 MFI 14.19±10.64 28.45±34.13 0.0078 
Data presented as mean ±SD; p<0.05 represented in boldface; MFI: Median fluorescence intensity. 
3.3.3. Increased levels of PMAs post stimulation with ADP in the control group 
Post-stimulation with ADP showed a significant decrease in %CD14 in the control group 17.99[8.46-
20.31] compared to the unstimulated levels 63.16[61.10-63.80], p=0.0074 (Table 3.3). There was no 
significant differences post stimulation with ADP in qualitative measurements (CD14 MFI). PMA 
levels (%CD41) were significantly increased post stimulation with ADP 25.97[20.02-33.22] compared 
to unstimulated levels 12.55[12.49-16.34], p=0.0438 (Table 3.3).  
Table 3.3. PMA levels post stimulation with ADP. 
Control diet Unstimulated Post-ADP p-value 
%CD14 63.16[61.10-63.80] 17.99[8.46-20.31] 0.0074 
CD14 MFI 6.13[5.98-6.55] 18.00[12.53-64.61] 0.2596 
%CD41 12.55[12.49-16.34] 25.97[20.02-33.22] 0.0438 
CD41 MFI 25.84[22.45-31.69] 34.22[24.06-41.80] 0.2854 
High-fat diet Unstimulated Post-ADP p-value 
%CD14 13.52[4.590-16.08] 14.37[8.430-18.98] 0.0405 
CD14 MFI 16.53[11.28-45.47] 20.32[14.66-73.78] 0.3125 
%CD41 29.96±11.40 28.94±10.79 0.4375 
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CD41 MFI 67.22±28.19 40.08±14.95 0.0938 
Data presented as mean ±SD; p<0.05 represented in boldface; MFI: Median fluorescence intensity; 
ADP: adenosine diphosphate. 
3.3.4. Increased levels of PMAs post stimulation with 20µM ADP in HFD group 
The HFD group showed a significant decrease in the %CD14 post stimulation with ADP 14.37[8.430-
18.98] compared to unstimulated levels 13.52[4.590-16.08], p=0.0405. Interestingly there was no 
significant difference between the unstimulated PMA levels 29.96±11.40 and post-ADP stimulation 
28.94±10.79, p=0.4375 (Table 3.3). 
3.4.  Discussion 
The aim of this study was to evaluate PMA formation in an HFD induced pre-diabetic mouse model. 
The C57BL/6 mice used were the ideal model for this study as they develop glucose intolerance when 
fed on an HFD (13) This study also aimed at elucidating a link between inflammation and the 
hypercoagulable state observed in diabetes. Although animals presented with nonsignificant differences 
in basic parameters such as body weight and insulin levels, markers indicating platelet activation 
enhanced. This result may suggest that pathogenesis of pre-diabetes leading to the development of 
T2DM may initiate even before individuals present significant changes in body weight or insulin levels. 
Overall, this study was able to demonstrate that in pre-diabetes, activated platelets readily interact with 
monocytes forming PMAs which have been described as early markers for atherosclerosis in T2DM 
(14). The formation of these aggregates at this early stage of pre-diabetes may indicate the hyperreactive 
nature of platelets which characterize the diabetic condition. We were able to demonstrate that activated 
platelets were capable of forming these interactions by flow cytometry measurements of platelet-bound 
monocytes. This is in agreement with previous studies which demonstrated that activated platelets 
interact with monocytes via P-selectin and its counter-receptor PSGL-1 expressed on the surface of 
monocytes (3,4,15). To the best of our knowledge, our study is the first to assess PMAs using a diet-
induced pre-diabetes animal model, which could significantly enhance our current understanding on the 
susceptibility of the vasculature to abnormally enhanced platelet activation. 
The animal experimental model showed that pre-diabetic mice exhibited elevated levels of PMAs, 
indicating increased interactions between platelets and monocytes than in non-diabetic states. The 
qualitative increase of the PMAs also reiterates the increased levels of platelet-monocyte interactions 
in the pre-diabetes which may promote thrombosis. A previous study showed that increased PMA levels 
in individuals who already had coronary artery disease (15). In any case, individuals with myocardial 
infarctions exhibit high levels of PMAs (16,17). It has been suggested that increased levels of PMA as 
well as platelet-neutrophil aggregates in T2DM further highlighting the importance of the platelet-
monocyte interactions in the progression of the pro-thrombotic state (12).  
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Consistently, in response to ADP stimulation, the pre-diabetic group exhibited an increase in the 
formation of PMAs indicating the hyperreactive nature of platelets in this disease state. ADP is a platelet 
agonist which activates the P2Y12 pathway resulting to its the translocation of P-selectin from the alpha 
granules to the cell surface (16,18,19). Activated platelets form interactions with monocytes, this is 
mediated by the binding of P-selectin to its receptor PSGL-1 on the surface of these cells (3). Platelet-
bound monocytes are activated and differentiated into pro-inflammatory monocytes. This is 
accompanied by an increase in the expression of CD11b, a marker of monocyte activation (3,16,20). 
To that effect, our study showed a decrease in CD14 monocyte marker, indicating a shift in the 
monocyte phenotype to the pro-inflammatory form CD14++ which can be explained by the higher 
qualitative analysis (CD14 MFI). 
The hyperreactive nature of platelets in pre-diabetes may be associated with increased PMA formation, 
the early marker of atherosclerosis that is known to promote a pro-inflammatory state (13,21). A 
drawback of this study may be that the levels of pro-inflammatory markers produced as a result of PMA 
formation were not determined. Further studies evaluating the monocyte pro-inflammatory response as 
a result of platelet binding interactions in pre-diabetes will provide insight into the role of these in the 
transmigration of monocytes into metabolic tissue.  
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3.9. Bridging chapter 
The formation of platelet monocyte aggregates provides a robust measurement of platelet activation. It 
gives a basis for further analysis on the functionality of the activated platelets in the following chapter. 
After determining increased platelet activation levels in pre-diabetes, we further elucidated on the role 
of platelet hyperactivity in pre-diabetes by measured platelet reactivity and function in response to 
stimulation of the P2Y, cyclooxygenase and glycoprotein VI mediated signalling pathways. 
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4. Abstract 
Background 
Platelet hyperactivity is associated with microvascular and macrovascular complications in type 2 
diabetics. Although such complications have been identified in pre-diabetes, the role of platelet activity 
in a pre-diabetic state is poorly understood. This study aimed at assessing the levels of platelet activation 
and function in a pre-diabetic mouse model to improve our understanding of mechanisms involved in 
the development of diabetes induced vascular damage.  
Methods 
A 60% high-fat diet (HFD) was used to induce pre-diabetes in C57BL/6 mice. Body weights, glucose 
tolerance, insulin levels and haematological parameters were measured after 3 weeks on the diet. In 
order to investigate platelet reactivity in HFD fed mice, their whole blood samples were stimulated with 
varying concentrations of adenosine diphosphate (ADP) and then stained with the platelet markers 
including glycoprotein IIb/IIIa (CD41), P-selectin (CD62P), and glycoprotein IV (CD36). 
Results 
Results showed that despite no significant differences in body weights, glucose tolerance was impaired 
in these pre-diabetic mice. There were no significant differences in the haematological parameters 
measured between the two study groups. Post-stimulation with different agonists concentrations 
resulted in elevated %CD62P expression in the HFD group.  
Conclusions 
The results show that despite not gaining weight, mice fed an HFD diet displayed impaired glucose 
tolerance and platelet reactivity. In addition to inferring that a pre-diabetic state may occur independent 
of weight gain in individuals, it also shows the high risk of such individuals in this state to develop 
cardiovascular complications. 
Keywords: Pre-diabetes; Platelet reactivity; Platelet function; Flow cytometry 
4.1. Introduction  
Type 2 diabetes mellitus (T2DM) is characterised by insulin resistance, hyperglycaemia, 
hyperinsulinemia and an increased incidence of microvascular and macrovascular complications (1,2). 
On the other hand, pre-diabetes is defined as a state of impaired glucose tolerance that is associated 
with at higher risk of developing T2DM (3,4). Previous studies have focused on the pathophysiological 
mechanisms in a pre-diabetic state, in efforts to identify interventions to curb diabetic complications 
that may lead to the development of cardiovascular disease (CVD). In pre-diabetic individuals, elevated 
levels of activated peripheral blood platelets have been associated with myocardial infarcts of coronary 
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artery disease (5,6). Although precise mechanisms involved in this process are not fully known, 
disturbances in several platelet signalling pathways such as adenosine diphosphate receptor (P2Y12) 
may initiate these irregularities (5,7). It is also reported that activated platelets play a crucial role in 
initiating inflammation, coagulation and subsequent thrombus formation through the actions of a cell 
adhesion molecule, P-selectin (8,9). Elevated levels of P-selectin have already been linked with an 
increased risk of coronary artery disease in individuals living with T2DM (5,10), suggesting that 
increased platelet activation plays a major role in the development of CVD. 
Platelets also express glycoprotein IV (CD36), a major platelet glycoprotein that is involved in 
thrombus formation (11,12). In resting platelets, CD36 is localised on the alpha granule membrane and 
the open canalicular system (13). Whereas on activated platelets, CD36 is densely expressed on 
pseudopods and the plasma membrane (13). The soluble form of CD36, sCD36, has been described as 
a novel biomarker of T2DM (14). Several other studies have shown that sCD36 is associated with the 
development of obesity, insulin resistance, increased risk of T2DM and atherosclerosis (14–16).  
Although elevated levels of both P-selectin and CD36 are linked with the aggravation of inflammation, 
comprehensive understanding of enhanced platelet-mediated responses in a pre-diabetic state remain 
unclear. However, it is currently understood that an elevated platelet reactivity index (PRI) may be 
associated with an increased incidence of long-term cardiovascular events (5,17). In this study, we 
aimed at assessing the role of platelet activation and function in a pre-diabetic state through the use of 
endogenous agonists which stimulate the purinergic receptor (P2Y12), phospholipase C (PLC) and 
cyclooxygenase (COX) platelet signalling pathways. 
4.2. Methodology 
4.2.1. Study design and animal care 
Male C57BL/6 mice (age: 5 weeks) were purchased from the University of KwaZulu-Natal (UKZN) 
biomedical research unit (BRU) and handled according to the principles of laboratory animal Care of 
the National Society of Medical Research and the National Institutes of Animal Care and Use of 
Laboratory Animals of the National Academy of Sciences (National Institute of Health publication 80-
23, revised 1978). Ethical clearance was granted by the UKZN animal research ethics committee 
(AREC), ethics registration number AREC/086/016.  
After the 1-week acclimatization period, the mice (n=18) were randomized into two diet groups and 
kept on the respective diets for a duration of 3 weeks. Mice in the experimental group (n=13) were fed 
a high-fat diet (HFD), which contained 60% kilocalories derived from fats (Research diet no. D12492; 
Research Diets, New Brunswick, NJ, USA). The control group (n=5) received a low-fat control diet 
containing 10% kilocalories fat (Research diet no. D12450J; Research Diets, New Brunswick, NJ, 
USA). Mice were housed in a controlled environment with a twelve-hour light/dark cycle (lights were 
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switched on at 6:00 AM and switched off at 6:00 PM) and a temperature range of 23-25ºC (relative 
humidity: ∼50%). The mice also had unlimited access to water. Furthermore, they were regularly 
monitored while the cages were cleaned once a week, to ensure a clean environment. 
4.2.2. Oral glucose tolerance tests 
After 3-weeks on HFD, all mice fasted for 8 hours before their fasting blood glucose levels were 
measured as previously described (18). Briefly, using oral gavage method, 2g/kg of glucose was 
administered, and blood glucose levels were measured at varying time intervals (0 minutes (baseline), 
30 minutes, 60 minutes, and 120 minutes), using the Accu-Check active blood glucometer (Roche, 
Basel, Switzerland). 
4.2.3. Blood collection  
After 3 weeks on the experimental diets (at 9 weeks of age), 200µl of venous blood was collected from 
the lateral tail vein. This was collected into 3.2% sodium citrate coated microtainer tubes (Sigma 
Aldrich, St Louis, Missouri, USA).  
4.2.4. Measurement of baseline haematological parameters 
The baseline haematological parameters which included the platelet counts and mean platelet volume 
were measured using the Beckman Coulter AcT diffTM analyser (Beckman Coulter, Brea, CA, USA), 
following manufacturer’s instructions. 
4.2.5. Platelet flow cytometry and platelet function analysis 
Flow cytometry analysis was performed within 30 minutes of blood collection. Internal quality control 
(QC) was performed using the Becton Dickson (BD) cytometer set-up and tracking (CST) beads (BD 
Bioscience, NJ, USA), as per manufacturer’s instructions. The BD ™ Compbead compensation 
particles were used to calculate and compensate for spectral overlap between the fluorescent channels. 
In addition, daily monitoring of potential instrumental drifts was performed using the SPHERO ™ 6-
peak Rainbow calibration particles (BD Bioscience, NJ, USA) and used as QC for all median 
fluorescence intensity (MFI) measurements.  
4.2.6. Baseline measurement of markers of platelet activation  
The baseline levels of circulating activated platelets were determined as previously described (19). 
Briefly, 25µl of whole blood was stained with 2.5µl of a titrated antibody cocktail containing 
glycoprotein IIb/IIIa, CD41-FITC (used as a platelet marker); P-selectin, CD62P-BV421 (used as a 
platelet activation marker) and glycoprotein IV, and CD36-PE (used as a platelet aggregation marker) 
(BD Bioscience, NJ, USA). The samples were then incubated at room temperature for 10 minutes and 
immediately analysed on the BD FACS Canto II flow cytometer (BD Bioscience, NJ, USA). 
43 
 
4.2.7. Platelet function analysis: Agonist-induced platelet activation 
Two varying concentrations of ADP (4µM for reversible and 20µM for irreversible platelet activation), 
collagen (0.19mg/mL) and arachidonic acid (500µg/mL) (irreversible single wave platelet activation) 
(Bio-data co-operation, Pennsylvania, USA) were used as previously described (19). Briefly, 25µl of 
whole blood was stimulated with 10µl of agonist in a staggered manner and incubated at room 
temperature for 15 minutes. The samples were then stained with 2.5µl of the antibody cocktail 
containing CD41-FITC (clone MWReg30), CD62P-BV421 (clone RB40.34), and CD36-PE (clone 
CRF D-2712) (BD Bioscience, New Jersey, USA) and incubated for 10 minutes in the dark, at room 
temperature. The lysis of red blood cells was omitted as this has been shown to induce platelet activation 
by releasing ADP as described by Helms et. al (20). Thus, 350µl of phosphate buffer saline was added 
before the sample analysed on the BD FACS Canto II flow cytometer (BD Bioscience, NJ, USA). The 
percentage expression (quantitative) and MFI (qualitative) of both markers (CD62P and CD36) were 
also measured. The PRI for each activation marker was calculated, using the baseline CD62P MFI and 
CD36 MFI according to the following equation. 
Platelet reactivity Index= (
MFI post Agonist stimulation -MFI at Baseline 
MFI post Agonist Simulation
 x 100).  
4.2.8 Gating strategy 
The platelet marker CD41 was used to gate on unbound, freely circulating platelets (PLT) with lower 
side scatter properties. The red-blood cell bound platelets (RBC-PLT) were also gated using CD41 
and higher side scatter properties. An unstained control was used to gate out autofluorescence. The 
level of level of activated, freely circulating platelets was determined by the membrane surface 
expression of activation marker CD62P (P-selectin) (Figure 4.1) 
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Figure 4.1. Platelet gating strategy. (a) The primary gating strategy was based on the platelet marker 
(CD41) used to distinguish platelet populations. The side scatter properties were used to distinguish 
unbound platelets (PLT) from red blood cell-bound (RBC-PLT) platelets. (b) The quantitative 
(%CD62P) and qualitative (CD62P MFI) expression of CD62P was determined. (e) Quantitative 
(%CD36) and qualitative (CD36 MFI) levels of CD36 expression on platelets was determined. (d) 
Quantitative (%CD41) and qualitative (CD41 MFI) red blood cell-bound platelet population was 
determined based on the RBC-PLT primary gate in (a). RBC: Red blood cell; RBC-PLT: Red blood 
cell-bound platelets; PLT: Platelet; MFI: Median fluorescence intensity. 
4.2.9 Statistical analysis 
All statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San Diego, 
California, USA). Parametric data were analysed using the repeated measures ANOVA and 
Bonferroni's Multiple Comparison Test post hoc test. Parametric data were reported as the mean ± 
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standard deviation (SD), and non-parametric data reported as the median ± interquartile range (IQR).  
4.3. Results 
4.3.1. Establishment of a pre-diabetic model 
There were no body weight differences between the HFD group and control diet mice (Table 4.1, Figure 
4.2). Notably, the basal levels of %CD62P and CD62P MFI were comparable between the two groups 
(Table 4.1). 
Table 4.1. Baseline parameters 
 Control group 
(n=5) 
HFD 
(n=13) 
p-value 
 
Body weight (g) 26.60± 3.44 27.07± 1.49 0.9648 
White cell count x 103/µL 7.2±3.49 8.471±2.84 0.5168 
Red blood cell count x 106/µL 7.33±0.3 6.24±1.21 0.0109 
Platelet count x 103/µL 923.3± 147.8 771.8± 147.8 0.0475 
Mean platelet volume (fL) 5.58± 0.42 5.39± 0.21 0.2673 
Plateletcrit (PCT) 0.49[0.42-0.59] 0.40[0.37-0.44] 0.0475 
Platelet distribution width (PDW) 0.055[0.053-0.059] 0.054[0.050-0.055] 0.2673 
%CD62P 6.43[3.88-9.86] 4.98[3.89-5.99] 0.5569 
CD62P MFI 95.93[73.03-111.5] 87.19[51.62-98.22] 0.2782 
%CD36 2.06±1.50 1.69±0.82 0.2127 
CD36 MFI 43.90±1.95 41.60±1.98 0.0475 
Significant values (p<0.05) are shown in bold. HFD: High-fat diet group; MFI: Median fluorescence 
intensity 
Overall, the oral glucose tolerance showed that the HFD group had a higher postprandial blood glucose 
levels compared to the control group. This was also illustrated by the higher area under the curve (AUC) 
observed in the HFD group (Figure 4.2). Notably, the HFD group showed significant levels of impaired 
glucose clearance at 30 minutes postprandial blood glucose levels (p=0.0233). There was also a 
decrease in the plateletcrit in the HFD group as compared to the control group, p=0.0475. While the 
baseline GPIV (CD36) MFI was reduced in the HFD group (p=0.0475) (Table 4.1). 
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Figure 4.2. Animal weight and glucose control. (a) The C57BL/6 mice showed a steady increase in weight with 
no significant difference between the 2 study groups. (b) The oral glucose tolerance test (OGTT) showed 
significant poor glycaemic control for the HFD group at 30minutes compared to the control group, p= 0.0233. (c) 
Overall, the area under the curve demonstrated increased poor glycaemic in the HFD compared to the control 
group, p= 0.0362. CTRL: Control diet group; HFD: High-fat diet group; AUC: area under the curve. 
For haematological parameters, the HFD group had lower red blood cell count compared to the control 
diet group, p=0.0109. Similarly, the HFD group had a lower platelet count compared to the control diet 
group, p=0.0475. The platelet count showed a positive correlation with the red blood cell count (RBC), 
r=0. 5504, p=0. 0414. There was a significant correlation between the red blood cell-bound platelet 
(RBC-PLT) and freely circulating platelets (PLT) post stimulation with arachidonic acid in the high-fat 
diet group (r=0.6233; p=0.0013) (Figure 4.4). No other significant correlations were observed with the 
other parameters measured, including mean platelet volume, plateletcrit and platelet distribution width 
(Figure 4.3 and 4.4). 
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Figure 4.3. Correlations between red blood cell-bound platelet and freely circulating platelets in the control diet 
group. (a) Correlation between RBC-PLT and PLT at baseline was statistically insignificant (r=0.0356; p=0.8113). 
(b) Post-stimulation with 4µM ADP, the correlation was also insignificant (r=0.0666; p=0.7420). (c) 20µM ADP 
stimulation did not elicit any significant correlation between the RBC-PLT and PLT populations (r=0.1942; 
p=0.5593). (d) The stimulation of platelets with collagen also provided no significant correlation between the two 
populations (r=0.0067; p=0.8963). (e) There was also no significant correlation between the populations post 
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stimulation with arachidonic acid (r=0.1699; p=0.4904). ADP: adenosine diphosphate; RBC-PLT: red blood cell-
bound platelets; PLT: freely circulating unbound platelets. 
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Figure 4.4. Correlations between red blood cell-bound platelet and freely circulating platelets in the high-fat diet 
group. (a) In this group baseline correlation between the red blood cell-bound platelets and freely circulating 
platelets was non-significant (r=0.0066; p=0.7925). (b) Stimulation of platelets with 4µM ADP, the correlation 
between the two populations was also non-significant (r=0.0953; p=0.3049). Similarly, post stimulation with 
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20µM ADP resulted in non-significant correlation between the populations (r=0.1297; p=0.2267). (d) Collagen 
platelet stimulation also did not elicit any significant correlation (r=0.1319; p=0.2225). (e) There was a significant 
positive correlation between the red blood cell-bound platelets and the freely circulating platelets post stimulation 
with Arachidonic acid (r=0.6233; p=0.0013). ADP: adenosine diphosphate; RBC-PLT: red blood cell-bound 
platelets; PLT: freely circulating unbound platelets. 
Quantitative analysis of the RBC-PLT population demonstrated significantly lower levels in the HFD 
group at baseline (p=0.0078), however, it was markedly increased post stimulation with arachidonic 
acid (p=0.0482) (Table 4.2). 
Table 4.2. Quantitative (%CD41) comparison of red blood cell-bound platelets between control and 
high-fat diet 
Agonist Control diet HFD p-value 
Baseline 4,565[3,075-10,45] 1,370[1,160-2,295] 0,0078 
4µM ADP 1,530[0,7350-1,925] 1,310 [0,7750-1,515] 0,6934 
20µMADP 1,310 [1,268-1,780] 1,690 [1,315- 2,125] 0,2572 
Collagen 3,170 [2,610- 3,945] 3,990 [3,535- 5,220] 0,0681 
Arachidonic acid 1,260 [0,0000- 5,335] 6,970 [2,305- 11,56] 0,0482 
Significant values (p<0.05) are shown in bold. HFD: High-fat diet group 
Qualitative analysis of this population also showed significantly lower levels in the HFD group 
(p=0.0273) and higher levels in the same group post stimulation with 4µM ADP (p=0.0487) (Table 
4.3).  
Table 4.3. Qualitative (CD41 MFI) comparison of red blood cell-bound platelets between control and 
high-fat diet 
Agonist Control diet HFD p-value 
Baseline 5652 [5225-6341] 4933 [4755-5330] 0,0273 
4µM ADP 4944 [4752-4998] 5162 [4980-5543] 0,0487 
20µM ADP 4488 [4377-5081] 4884 [4555-5249] 0,1570 
Collagen 5385 [4854-5535] 5164 [4992-5342] 0,6221 
Arachidonic acid 4630 [0,0000-6020] 6423 [4575-7422] 0,1384 
Significant values (p<0.05) are shown in bold. HFD: High-fat diet group; MFI: Median fluorescence 
intensity 
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4.3.2. Platelet activation post stimulation with ADP 
To evaluate the ability of platelets to undergo dose-dependent reversible and irreversible activation, 
platelets were stimulated using two ADP concentrations, 4µM and 20µM. The HFD group showed a 
comparable response after stimulation with 4µM ADP 2.22[0.79-3.09] and 20µM ADP 1.44[0.60-2.58], 
p=0.0956. However, post stimulation with 4µM ADP and 20µM ADP, the HFD group expressed 
elevated %CD62P compared to the control group 0.35[0.22-0.76], p =0.0020 and p=0.0052 respectively 
(Figure 4.5). In addition, the HFD group had a higher CD36 PRI compared to the control group, 
p=0.0362.  
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Figure 4.5. Biphasic platelet activation post stimulation with 4µM and 20µM ADP. The levels of 
platelet CD62P and CD36 at baseline and post stimulation with varying concentrations of ADP. (a) 
Stimulation with 4µM (p=0.0020) and 20µM (p=0.0052) increased levels of %CD62P in HFD group. 
(b) The MFI levels in the HFD group were significantly decreased post stimulation with 4µM ADP but 
remained comparable across all other groups. (c) Stimulation with 20µM ADP resulted in a decrease in 
the %CD36 expression in the control group, p=0.0286. (d) While stimulation with the 20µM of ADP, 
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significantly decreased the CD36 MFI in the HFD group. #: p<0.05 4µM ADP vs 20µM ADP; *: p<0.05 
Baseline vs 4µM ADP; **: p<0.05 Baseline vs 20µM ADP; Ctrl: control group; HFD: High fat diet 
group; MFI: Median fluorescence intensity. 
4.3.3. Increased levels of platelet activation (%CD62P) and reactivity in response to 
endogenous agonists in HFD group 
In order to determine the level of platelet activation post stimulation with endogenous agonists collagen 
and arachidonic acid, we measured the percentage expression of CD62P and the corresponding MFI.  
Table 4.4. Platelet reactivity post stimulation with endogenous agonists 
Agonist %CD62P CD62 MFI 
Control 
group 
HFD p-value Control 
group 
HFD p-value 
Collagen 1,05 [0,31 -
2,84] 
14,61 
[6,041-20,21 
0,0475 0,39 [0,10- 
0,51] 
-0,05 [-0,10-
0,03] 
0,0007 
Arachidonic 
acid 
19,30 
[14,32-
28,59] * 
6,82 [2,96-
16,12] 
0,4617 -0,01 [-0,34-
0,45] 
0,07 [-0,04-
0,23] * 
0,0519 
 %CD36 CD36 MFI 
Control 
group 
HFD p-value Control 
group 
HFD p-value 
Collagen -0,30[-0,41- 
-0,17] 
0,39[0,15-
0,55] 
0,2263 -0,04[-0,12- 
-0,01] 
0,02[-0,06-
0,04] 
0,2157 
Arachidonic 
acid 
4,25[3,43-
4,69] * 
7,78[6,02-
9,01] * 
0,3512 4,73[1,22-
12,64] 
1,14[0,89-
1,64] * 
0,0088 
Significant values (p<0.05) are shown in bold and with an asterisk (*). HFD: High-fat diet group; MFI: 
Median fluorescence intensity 
At post-stimulation with collagen, the %CD62P expression was higher in the HFD group 4.58[3.89-
6.04] compared to the control group 1.50[1.34–2.02], p=0.0195. Similarly, the CD62P MFI was 
elevated in the HFD group compared to the control diet group, p=0.0016. Arachidonic acid stimulation 
also resulted in higher %CD62P expression in the control group 10.20[4.69-31.82] compared to the 
HFD group 2.70[1.79-6.77], p=0.0301 (Table 4.5). 
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Table 4.5: CD62P expression post stimulation with collagen and arachidonic acid 
 CTRL HFD p-value 
Collagen    
%CD62P 1,50 [1,34 - 2,02] 4,58[3,89- 6,04] 0,0016 
CD62P MFI 2640 [2383 - 2677] 1643 [1586 - 1709] 0,0016 
Arachidonic acid    
%CD62P 10,20 [4,69- 31,82] 2,70[1,79- 6,77] 0,0301 
CD62P MFI 1916 [1611 - 2437] 1793 [1710 - 2093] 0,7674 
Significant values (p<0.05) are shown in bold; CTRL: Control diet group; HFD: High-fat diet group; 
MFI: Median fluorescence intensity. 
4.3.4. Increased CD36 expression post stimulation with agonists in HFD group 
The expression of CD36 was determined both quantitatively (%CD36) and qualitatively (CD36 MFI) 
post stimulation with collagen and arachidonic acid. The HFD group had lower CD36 MFI expression 
compared to the control group, p=0.0193 (Table 4.6, Figure 4.6). 
Table 4.6: CD36 expression post stimulation with collagen and arachidonic acid 
 CTRL HFD p-value 
Collagen    
%CD36 11,92 [10,67-13,18] 12,69 [11,58-16,84] 0,2369 
CD36 MFI 48,99 [48,62-50,25] 49,51 [48,97-50,16] 0,4902 
Arachidonic acid    
%CD36 91,44 [78,99-97,64] 95,11 [90,46-96,54] 0,3562 
CD36 MFI 201,9 [91,63-612,2] 109,1 [95,45-127,2] 0,0193 
Significant values (p<0.05) are shown in bold; CTRL: Control diet group; HFD: High-fat diet group; 
MFI: Median fluorescence intensity 
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Figure 4.6. Platelet activation and function post stimulation with collagen and arachidonic acid. (a) 
Increased platelet %CD62P compared to the control (Ctrl) post stimulation with collagen (p=0.0016) 
and decreased post arachidonic acid stimulation (p=0.0301). (b) The CD62P MFI was decreased in the 
HFD group compared to the control group post stimulation with collagen (p=0.0016). Post-stimulation 
with arachidonic acid had increased CD62P MFI compared to collagen post stimulation in the HFD 
group (p=0.0046). (c) There was higher platelet %CD36 expression post stimulation with arachidonic 
acid compared to collagen stimulation (p=0.0002). (d) Increased platelet CD36 MFI post stimulation 
with arachidonic acid was higher than collagen, in the HFD group (p=0.0002). The HFD group had 
lower CD36 MFI compared to the control group, p=0.0193. *Ctrl vs HFD (Arachidonic acid); **Ctrl 
vs HFD (Collagen); # p<0.05 Collagen vs Arachidonic acid (HFD). 
4.4. Discussion 
The aim of this study was to investigate the role of platelet activation and function in an HFD-induced 
pre-diabetic mouse model. Previous research shows that male C57BL/6 mouse strain can develop 
obesity, impaired glucose tolerance and insulin resistance during high-fat feeding (21). In our study, 3-
weeks of high-fat feeding in mice led to the development of impaired postprandial glucose control, a 
common feature of pre-diabetes (22). Although mice did not gain significant weight, such 
54 
 
characteristics have been identified in non-obese individuals with T2DM, where it was shown that these 
individuals may develop insulin resistance more rapidly as compared with obese counterparts (23). 
Nonetheless, haematological indices measured, which included RBC, platelet count and the plateletcrit, 
were all decreased in the HFD fed group when compared to the controls. These findings suggest that 
pre-diabetic mice might have developed thrombocytopenia. Interestingly, it has been shown that a 
diabetic state can increase the severity of thrombocytopenia in dengue virus-infected individuals in the 
first three days of hospitalisation (24).  
It is currently known that platelets are essential for haemostasis, especially in preserving healthy 
vascular endothelium (25). However, together with the low RBCs, decreased platelet count in a diabetic 
state may indicate dysfunctional coagulation cascade (25). Our analysis of the red blood cell-bound 
platelets demonstrated no relationship at baseline but was increased when stimulated with arachidonic 
acid in the HFD fed group. Interestingly, despite the differences in basal platelet counts, in our study, 
the baseline levels of activated platelets were comparable between the pre-diabetic and experimental 
control group. A similar finding was reported by Dogru and colleagues, where they showed no 
significant differences in basal levels of sP-selectin levels between pre-diabetic and non-diabetic 
individuals (26). The use of P-selectin and ADP to study platelet activation in mice may provide 
evidence of the hyperreactivity of platelets from pre-diabetes despite normal basal activation levels. 
In the current study, a biphasic response was observed post-ADP stimulation in the pre-diabetic group. 
This effect suggests that sub-threshold concentration of ADP was able to elicit maximum platelet 
response which may indicate high platelet susceptibility to submaximal stimulation in the pre-diabetic 
state. Briefly, ADP is known to be released from platelet dense granules in response to inside-out PLC 
signalling, this subsequently leads to platelet shape change and aggregation (27,28). During this 
process, the integrin αIIbβ3 undergoes conformational changes resulting in a high-affinity state for 
attachment to fibrinogen resulting in platelet aggregation (29). The Gq-coupled protein P2Y1 is an ADP 
receptor, which activates the release of calcium from the dense tubular system (DTS) leading to platelet 
activation, reversible aggregation and shape change. A previous study identified increased levels of 
intracellular cytosolic Ca2+ following ADP and thrombin stimulation in mice lacking P2Y1 (30). It is 
also reported that hyperglycaemia can alter Ca2+ mobilisation and ultimately promote its reactivity with 
aggregation agents [31, 32]. In diabetic individuals, platelets can exhibit reduced membrane fluidity as 
a result of modifications in lipid components or glycation of membrane proteins, as well as an increase 
in intracellular Ca2+ mobilisation (33). The glycation of membrane proteins may then cause changes in 
protein structure and conformation enhancing the expression of platelet receptors such as P-selectin 
(31). In our study, we activated the P2Y12 receptors with the ADP agonist and hence we can hypothesise 
that intracellular Ca2+ levels were increased. As a result, we observed elevated platelet activation levels. 
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In our study, platelet reactivity was also increased in pre-diabetic mice post stimulation with arachidonic 
acid. Stimulation with this agonist resulted in a higher PRI in pre-diabetic mice, with an overall 
increased expression of both P-selectin and CD36 when compared to the controls. Arachidonic acid is 
known to induce platelet aggregation and release of thromboxane A2 (TXA2), which is associated with 
detrimental effects through the generation of oxidative stress and activation of the PLC pathway (34). 
Thus, peroxidation of arachidonic acid forming active isoprostanes may provide an important 
connection between impaired glucose tolerance and platelet activation. Oxidative stress induced by the 
chronic hyperglycaemia in pre-diabetes enhances peroxidation of arachidonic acid and the production 
of prostaglandins and thromboxanes (35–37). Interestingly, as a previous study showed a negative 
correlation between arachidonic levels in blood and glycated haemoglobin (38). This may suggest that 
poor glucose control such that observed in a pre-diabetic state may influence platelet activation through 
thromboxane mediated signalling (38). However, further studies are needed to study this phenomenon 
in detail. 
Furthermore, we studied another major platelet glycoprotein, CD36, and its involvement in thrombus 
formation in our model. CD36 is involved in platelet aggregation, adhesion to collagen and angiogenesis 
which contribute to the progression of atherosclerosis in T2DM (39,40). The present study 
demonstrated an inverse association between the qualitative and quantitative measurements of CD36. 
Currently, it is known that increased expression of CD36 correlates with markers of inflammation, 
which include high sensitivity C-reactive protein (hsCRP) and high sensitivity interleukin-6 (hsIL-6) 
which are independent predictors of CVD (41). Diabetic individuals display increased levels of sCD36 
compared to non-diabetic individuals, which have been linked with insulin resistance and obesity-
driven low-grade inflammation (14). Contrary to these findings, no significant changes in the expression 
of CD36 concomitant to reduced platelet activation have been observed in diabetic individuals 
following 3 months of improved glucose control (39). This may suggest that improved metabolic 
control alone may not be enough to normalise the levels of platelet function in people with T2DM. 
However, such findings have to be confirmed in other models of pre-diabetes. 
Nonetheless, our findings demonstrate that platelets from pre-diabetic mice were more reactive 
compared to those from the control group. This suggests that thrombotic complications such as platelet 
hyper-reactivity that are associated with hyperglycaemia and insulin resistance may develop as earlier 
as the pre-diabetic state. Our results further suggest that multiple signalling pathways in addition to the 
purinergic receptors may mediate platelet activation and function. However, before such hypothesis can 
be accepted, investigations to evaluate the involvement of platelet-leukocyte aggregates and platelet 
microparticles, which are a major contributor of circulating soluble glycoprotein IV and early 
biomarkers of T2DM are necessary (42). Future studies can also investigate the intracellular 
mechanisms involved in leukocyte-platelet interactions in a pre-diabetic state as this may provide 
further insight into the pathophysiology involved in platelet function in a pre-diabetic state. 
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4.5. Conclusion 
Platelet hyperreactivity is a common feature of pre-diabetes and T2DM (43), which consequently 
increases the risk of developing CVD (7). Platelet activation involves a convergence of several 
activation pathways. Our study showed that in a pre-diabetic state, platelets are hyper-reactive to 
arachidonic acid compared to ADP and collagen. This may suggest that the COX-1 regulated signalling 
pathway is highly activated in pre-diabetics and early anti-platelet treatment interventions targeting this 
pathway in pre-diabetic individuals may lower the risk of thrombotic complications in overt diabetes. 
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4.9. Bridging chapter 
In pre-diabetes, platelets exhibited hyperreactivity to stimulation of the purinergic receptor, 
glycoprotein VI and cyclooxygenase mediated signalling pathways. The hyperreactivity of platelets in 
this early stage of pre-diabetes may be the major driver of atherosclerotic conditions and cardiovascular 
disease at later stages in the progression into overt type 2 diabetes. The occurrence of cardiovascular 
disease in treated type 2 diabetes has been reported and persistent platelet reactivity may be a major 
role player in this phenomenon. The following study investigated the effect of combinational use of 
metformin and low-dose dual therapy in inhibiting platelet hyperreactivity to protect against diabetes-
induced vascular complications. Treatment with low-dose aspirin and clopidogrel agents was used as a 
comparative therapy. 
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5. Abstract 
Introduction 
Aspirin is a common drug used in the prevention of cardiovascular disease (CVD), whereas metformin 
is used to improve glucose homeostasis in type 2 diabetic patients. There is currently limited evidence 
on the effects and benefits of combined of metformin and low-dose aspirin therapy in reducing diabetes-
associated cardiovascular complications. This study investigated the platelet function in the combined 
metformin and low-dose aspirin therapy, in comparison we further evaluated clopidogrel a commonly 
used anti-platelet drug. 
Methods 
Pre-diabetic mice were randomized into different treatment groups; combination therapy of metformin 
(150mg/kg) and low-dose aspirin (3mg/kg) (n=5), low-dose aspirin (3mg/kg) (n=5) or clopidogrel 
(0.25mg/kg) (n=5) monotherapy. Baseline measurements were taken before treatment and 4 weeks after 
treatment, the body weights and insulin levels were again measured. Platelet function was assessed 
using varying concentrations of ADP (4µM and 20µM), collagen (0.19mg/mL) and arachidonic acid 
(500µg/mL). 
Results 
The animal body weights were comparable across the groups (p>0.05). The dual-treatment with 
metformin and low-dose aspirin inhibited platelet activation post stimulation with 4µM ADP 
(p=0.0220). Interestingly, the low-dose aspirin-treated group showed no significant difference in the 
residual levels of platelet activation post stimulation with both ADP concentrations (p>0.05). 
Clopidogrel treatment inhibited the response to collagen stimulation (p=0.0270). 
Discussion 
Our study showed varied platelet response to agonist-induced activation in the pre-diabetic group 
despite treatment. This highlights the involvement of different signalling pathways in platelet activation 
and the potential benefit of dual-therapy in pre-diabetes. The synergistic use of metformin and low-dose 
aspirin led to greater inhibition of platelet activation compared to low-dose aspirin monotherapy 
treatment. 
Keywords: Pre-diabetes; platelet reactivity; dual-therapy 
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5.1. Introduction 
People living with type 2 diabetes mellitus (T2DM) are at a higher risk of developing cardiovascular 
disease compared to nondiabetic individuals (1). There is no specific treatment currently available to 
protect diabetic individuals at risk of cardiovascular complications (2,3). However, conventional 
therapies that target both T2DM and cardiovascular disease are used to prolong the lives of diabetic 
patients. In fact, low-dose aspirin is used in the primary prevention of cardiovascular complications and 
subclinical atherosclerosis in patients with T2DM, who may be at risk of developing vascular events 
(4). While the use of low-dose aspirin is recommended in the prevention of cardiovascular events (4,5), 
cyclooxygenase (COX) and P2Y12 receptor inhibitors such as clopidogrel are the commonly used anti-
platelet drugs to prevent such complications (6,7). Alarmingly, a sub-optimal response to low-dose 
aspirin and clopidogrel treatments has been reported in T2DM patients with coronary artery disease (8–
10). Residual platelet activation persists in type 2 diabetics who are on low-dose aspirin (11).  
Interestingly, the use of a combination of metformin and low-dose aspirin can ameliorate diabetes-
associated complications, involving lipogenesis and hepatic glucose production, leading to improved 
insulin sensitivity (12,13). Metformin acts on the liver and the gut to lower glucose production and 
enhance glucose utilization (14). Furthermore, metformin lowers the cardiovascular mortality rate in 
diabetic patients (15). The use of metformin in combination with low-aspirin reduces the levels of 
urinary thromboxane A2 metabolite (11-dehydrothromboxane B2) which is directly associated with the 
levels of sCD40L, a platelet activation marker (13,16).  
Clopidogrel acts on blood platelets by inhibiting the P2Y12 receptor, thus preventing the binding of 
adenosine diphosphate (ADP) and consequently inhibit platelet activation (17–19). This process inhibits 
the function of platelet-monocyte aggregates (PMAs), which are associated with cardiovascular 
complications in T2DM associated (17–19). The therapeutic benefits of clopidogrel in people living 
with T2DM include a reduction in the relative risk of developing myocardial infarcts and strokes (20).  
Although the benefits of dual metformin and low-dose aspirin therapy include, reduced in platelet 
hyperreactivity and chronic inflammation (16), high on-treatment platelet reactivity (HTPR) has been 
associated with thrombotic complications in T2DM patients on combined aspirin and clopidogrel 
treatment (21). There is minimal data available on combinational effects of metformin and low dose 
aspirin in protecting against diabetes-induced cardiovascular complications. In this study, we assessed 
platelet activation and reactivity in pre-diabetes following combined metformin and low-dose aspirin 
treatment, as well as clopidogrel monotherapy.  
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5.2. Methodology 
5.2.1. Animal husbandry 
A total of 20 C57BL/6 male mice were purchased from the University of KwaZulu-Natal (UKZN) 
biomedical research unit (BRU). The mice were housed in a controlled environment with a twelve-hour 
light/dark cycle (lights were switched on at 6:00 AM and switched off at 6:00 PM) and a temperature 
range of 23-25ºC (relative humidity: ∼50%). All study procedures and animal handling were performed 
according to the principles of laboratory animal Care of the National Society of Medical Research and 
the National Institutes of Animal Care and Use of Laboratory Animals of the National Academy of 
Sciences (National Institute of Health publication 80-23, revised 1978). Ethical clearance for the study 
was obtained from the UKZN animal research ethics committee (AREC), ethics registration number 
AREC/086/016.  
5.2.2. Induction of pre-diabetes and experimental design 
The control group (n=5) was fed on a low-fat diet containing 10% Kcal fat (Research diet no. D12450J, 
Research Diets, New Brunswick, NJ, USA). While the high-fat diet experimental groups (n=15/group) 
were kept on a high-fat diet containing 60% Kcal fat (Research diet no. D12492, Research Diets, New 
Brunswick, NJ, USA). 
5.2.3. Treatment randomization and oral glucose tolerance testing 
The high-fat diet (HFD) fed mice (n=15) were then randomized into 3 treatment groups (n=5/group); 
metformin and low-dose aspirin (150mg/kg metformin + 3mg/kg aspirin); low-dose aspirin (3mg/kg 
aspirin), and clopidogrel (0.25mg/kg). All treatment drugs were administered daily via oral gavage, 
once a day daily for 4 weeks. Glucose tolerance was assessed in both control and the HFD-fed mice as 
previously described (22). Briefly, using oral gavage method, 2g/kg of glucose was administered, and 
blood glucose levels were measured at varying time intervals (30 minutes, 60 minutes, and 120 minutes) 
using the Accu-Check active blood glucometer (Roche, Basel, Switzerland). 
5.2.4. Blood collection and measurement of baseline haematological parameters 
A total of 200µl of venous blood was collected from the lateral tail vein into 3.2% sodium citrate coated 
microtainer tubes (Sigma Aldrich, St Louis, Missouri, USA). Baseline haematological parameters 
which included the platelet counts, mean platelet volume, were measured before treatment using the 
Beckman Coulter AcT diffTM analyser (Beckman Coulter, Brea, CA, USA).  
5.2.5. Platelet function and reactivity measurements 
5.2.6. Measurements of baseline platelet activation and reactivity  
Twenty-five microliters of blood was stained with an antibody cocktail containing CD41-FITC (1:10; 
clone MWReg30), CD62P-BV421 (1:10; clone RB40.34), and CD36-PE (1:10; clone CRF D-2712) 
(BD Bioscience, New Jersey, USA. In order to avoid the release of ADP and subsequent artefactual 
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activation of platelets, the red blood cells were not lysed (23). The samples were then incubated for 10 
minutes at room temperature before the samples were suspended in 350µl of PBS. Samples were then 
immediately analyzed on the BD FACS Canto II flow cytometer (BD Bioscience, NJ, USA).  
5.2.7. Assessment of platelet function 
Two varying concentrations of ADP were used to assess platelet purinergic receptor-mediated platelet 
activation. These concentrations are known to induce reversible (4µM) and irreversible (20µM) platelet 
activation (24). Collagen (0.19mg/mL) and arachidonic acid (500µg/mL) (Bio-data co-operation, 
Pennsylvania, USA) were used to stimulate irreversible platelet activation via the glycoprotein VI 
(GPVI) receptor and COX signalling pathway respectively (25). The platelet reactivity index (PRI) for 
CD62P and CD36 was calculated as follows: 
PRI= (
(%levels of CD62P/CD36 post stimulation)-(Basal % levels of CD62P/CD36)
(%levels of CD62P/CD36 post stimulation)
). 
5.2.8. Statistical analysis 
All statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San Diego, 
California, USA). Parametric data were analysed using the repeated measures ANOVA and 
Bonferroni's Multiple Comparison Test post hoc test. Non-parametric data were analysed using the 
Kruskal-Wallis test and Dunns post-test. Parametric data were reported as the mean ± standard deviation 
(SD), and non-parametric data reported as the median and interquartile range (IQR) 
5.3. Results 
5.3.1. Establishment of a pre-diabetic model 
The oral glucose tolerance test (OGTT) showed that the HFD group had a higher postprandial blood 
glucose levels compared to the control group. This was also illustrated by the higher area under the 
curve (AUC) observed in the HFD group indicating delayed blood glucose clearance in the HFD pre-
diabetic group (p=0.0362). There were no differences in the insulin levels and body weights between 
the treatment groups (p=0.0675) (Table 5.1). 
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Table 5.1. Baseline characteristics of pre-diabetic mice and controls 
Parameter Control (n=5) High-fat diet group Asp (n=5) Met + Asp (n=5) Clo (n=5) p-value 
Body weight (g) 30.0[23.5-31.0] 27.07± 1.49 26.0[26.0-27.0] 30.0[30.0-31.5] 28.0[27.3-29.5] 0.0675 
Insulin µIU/ml 16.16[15.43- 
22.71] 
 
 
16.43 [14.36- 
22,46] 
 23.96[16.11-
24.61] 
16.65[16.21-
17.97] 
13.73[13.68-
13.78] 
0.2667 
White cell count 
(103/µl)  
6.1[5.1-7.7] 8.471±2.84 8.3[7.7-8.9] 6.7[6.2-9.4] 7.6[4.9-11.1] 0.4269 
Red blood cell count 
(106/µl) 
7.1[6.1-7.5] 6.24±1.21 7.6[6.9-8.1] 7.6[7.2-7.8] 7.5[6.9-7.8] 0.3597 
Mean cell volume (fL) 42.0[41.5-43.0] 5.39± 0.21 41.0[40.5-42.0] 42.0[42.0-43.0] 40.5[39.3-42.5] 0.1049 
Haematocrit (%) 30.3[25.7-32.2] 29.00[23.00-31.40] 31.0[28.8-33.3] 31.9[29.9-33.4] 31.0[27.2-32.2] 0.5820 
Red blood cell 
distribution width (%) 
10.6[10.4-11.2] 11.05[10.63- 11.88] 11.3[10.8-11.6] 10.4[10.3-12.0] 11.7[10.9-13.4] 0.2821 
Neutrophil (%) 13.5[8.6-16.2] 8.00[6.90-9.30] 8.6[6.4-9.3] 11.3[8.6-16.8] 7.4[6.1-8.9] 0.0363 
Lymphocyte (%) 82.5[79.1-88.8] 89.20[87.80-90.50] 87.2[86.5-89.7] 82.6[77.4-87.0] 87.7[85.8-88.5] 0.1131 
Monocyte (%) 3.7[2.4-4.6] 3.95[3.48-5.13] 3.8[3.2-4.4] 4.1[3.5-5.9] 4.9[3.1-6.9] 0.4012 
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Basophil (%) 0.2[0.1-0.3] 0.20[0.10-0.80] 0.2[0.2-0.3] 0.2[0.2-0.3] 0.3[0.2-0.4] 0.3808 
Platelet count (103/µl) 803.0[669.5-988.5] 771.8± 147.8 956.0[850.5-
1027] 
805.0[672.5-
999.0] 
913.0[752.5-
1013] 
0.6104 
Mean platelet volume 
(fL) 
5.4[5.1-5.4] 5.39± 0.21 5.2[5.1-5.2] 5.2[5.2-5.4] 5.4[5.2-5.5] 0.2427 
%CD62P 91.87 [58.34- 94.76] 82.69[66.17- 93.15] 84.89[68.53- 
92.19] 
93.40[84.99- 
95.11] 
59.10[49.07-
76.98] 
0.1419 
CD62P MFI 105.2 [105.1- 111.1] 105.3 [105.0- 106.0] 105.5[105.3-
112.5] 
105.3[105.0-
106.1] 
105.0[105.0-
105.2] 
0.1390 
%CD36 35.70[25.53-48.37] 25.95[21.71-32.91] 26.98[25.55-
50.51] 
28.04[24.06-
34.84] 
19.20[17.29-
22.08] 
0.0513 
CD36 MFI 134.8[121.9-172.3] 199.4[172.7-213.6] 198.7[175.1-
201.6] 
221.1[165.1-
240.1] 
191.4[175.4-
209.4] 
0.0580 
p<0.05 represented in boldface (control vs treatment groups); values represented as median [IQR] or mean±SD; Met + Asp: metformin and low-dose aspirin 
dual therapy; MFI: Median fluorescence intensity; Clo: Clopidogrel; MFI: median fluorescence intensity. 
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5.3.2. P2Y12 receptor responses in HFD-fed mice following metformin and low-dose aspirin 
treatment 
In order to assess the P2Y12 receptor-mediated response, the levels of P-selectin (%CD62P) were 
measured post stimulation with 4µM and 20µM of ADP. In the metformin and low-dose aspirin-treated 
group, the platelet P2Y12 receptor-mediated %CD62P expression was only inhibited at 4µM of ADP 
(p=0.0220). Residual platelet activation was observed at the concentration of 20µM ADP (p=0.0535) 
(Table 5.2). Whereas the levels of %CD36 expression were only inhibited at a concentration of 20µM 
ADP (p=0.0002). Furthermore, the glycoprotein GPVI- mediated responses were also inhibited 
following the 4-week metformin and low-dose aspirin treatment (p=0.0329).  
5.3.3. P2Y12 receptor responses in HFD-fed mice following on low-dose aspirin treatment 
In the low-dose aspirin group, there were no significant variations in the %CD62P and %CD36 
expression following stimulation with ADP (p>0.05). Collagen was used to stimulate platelet GPVI 
receptor-mediated platelet activation. No significant difference in the %CD62P expression from the 
low-dose aspirin-treated post stimulation with collagen compared to pre-treatment levels (p=0.1396). 
5.3.4. P2Y12 receptor responses in HFD-fed mice following clopidogrel treatment 
Clopidogrel treatment only inhibited the platelet response to 20µM ADP (p=0.0313) (Table 5.2). 
Variations in P2Y12 receptor-mediated platelet responses across the treatment groups were assessed and 
the %CD62P platelet reactivity index (%CD62P PRI) was compared across the metformin and low-
dose aspirin group. A higher %CD62P PRI was observed in the metformin and low-dose aspirin group 
compared to the low-dose aspirin-treated group, post stimulation with 20µM ADP (p=0.0001) (Figure 
5.1). 
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Table 5.2. %CD62P platelet response in low-dose aspirin, metformin and low-dose aspirin, clopidogrel-treated pre-diabetic mice 
 CD62P platelet reactivity index (PRI) 
Agonist Pre-treatment Low-dose aspirin Pre-treatment Met + Asp  Pre-treatment Clopidogrel 
4µM ADP 2.388[-0.8050-
3.490] 
-0.6911[-0.7449--
0.6272] 
0.8182[0.1007-
3.531] 
-0.7343[-0.7716--
0.6956] a 
7.289[2.561-
9.655] 
-0.6669[-0.7396--
0.6471] 
20µM ADP 1.541[-0.8182-
4.117] 
-0.9516[-0.9633--
0.9390] 
2.529[0.1007-
4.897] 
-0.7400[-0.7675--
0.7266] 
5.974[2.909-
6.310] 
-0.6821[-0.7452--
0.6089] a 
Collagen 5.987[-0.5918-
12.48] 
-0.6390[-0.6957--
0.5968] 
14.64[5.416-
28.47] 
-0.7029[-0.7593--
0.6345] a 
14.61[11.00-
20.21] 
-0.8860[-0.9128--
0.7689] a 
Arachidonic acid 2.823[0.3519-
0.3519] 
-0.9913[-0.9945--
0.9639] a 
11.33[5.178-
16.77] 
-0.9953[-0.9966--
0.9466] a 
8.310[1.879-
23.26] 
-0.9712[-0.9915--
0.8765] 
a: p<0.05 pre-treatment vs treated groups (low-dose aspirin, Met + Asp and Clopidogrel). Values represented as median [IQR]; Met + Asp: metformin and low-
dose aspirin dual therapy; ADP: adenosine diphosphate. 
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Figure 5.1. Platelet reactivity index in low-dose aspirin (monotherapy) and dual therapy (Metformin + low-dose 
aspirin). (A) Post-stimulation with 4µM adenosine diphosphate (ADP), there were no significant differences in 
the platelet reactivity between low-dose aspirin and dual metformin + low-dose aspirin-treated group. (B) Low-
dose aspirin significantly lowered the platelet reactivity index compared to dual metformin + low-dose aspirin 
therapy at post stimulation with 20µM ADP (p=0.0001). There were no significant differences between the two 
therapies post stimulation with collagen and arachidonic acid (p>0.05), respectively (C) and (D). 
5.3.5. Glycoprotein VI mediated responses in HFD-fed mice following low-dose aspirin and 
clopidogrel treatment 
Clopidogrel treatment, similar to the other therapies, inhibited the response to collagen stimulation 
(p=0.0270) (Table 5.2). Clopidogrel inhibited the platelet response to both 4µM (p=0.0165) and 20µM 
ADP (p=0.0108) (Table 5.3). Clopidogrel did not significantly inhibit the %CD36 expression 
(p=0.1949). Low-dose aspirin significantly inhibited %CD36 PRI post stimulation with collagen 
compared to combined therapy (p=0.0416) (Figure 5.2).  
72 
 
 
Figure 5.2. Effects of monotherapy and dual therapy platelet on reactivity. (A) and (B) Post stimulation with 4µM 
and 20 µM ADP, there was no significant difference between monotherapy and dual therapy treated group. (C) 
There was a significant decrease in reactivity in the low-dose aspirin monotherapy group compared to the 
metformin and low-dose aspirin dual therapy treated group. (D) There were no significant differences between 
the two therapies post stimulation with arachidonic acid. *p<0.05; ADP: adenosine diphosphate, Asp: low-dose 
aspirin monotherapy; Met + Asp: metformin and low-dose aspirin dual therapy. 
5.3.6. Cyclooxygenase pathway response 
In the low-dose aspirin group, no significant inhibition of %CD36 expression was observed post 
stimulation with arachidonic acid (p=0.2509). Interestingly, in the metformin and low-dose aspirin 
group, the %CD36 PRI post stimulation with arachidonic acid was significantly lower compared to 
baseline (p<0.0001). Similar findings were observed in the clopidogrel group where %CD36 PRI post 
stimulation with arachidonic acid was lower than baseline pretreatment PRI (p=0.0108) (Table 5.3). In 
the low-dose aspirin group, the COX-dependent platelet activation was also inhibited as shown by the 
reduced %CD62P expression (p=0.0106) (table 5.2), whereas the levels of %CD36 were not affected 
(p=0.2509) (table 5.3). 
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Table 5.3: %CD36 platelet reactivity in response to agonist stimulation 
Agonist Baseline 
Pre-treatment 
Low-dose aspirin p-value 
4µM ADP -0.2739[-0.5367-2.337] -0.9937[-0.9956--0.9858] 0.1956 
20µM ADP -0.2659[-0.4537-2.216] -0.9957[-0.9969--0.9925] 0.1767 
Collagen 0.2442 [-0.3304-2.931] -0.9889[-0.9908--0.9871] 0.1387 
Arachidonic 
acid 
5.976[4.635-33.01] 1.570[0.4057-1.893] 0.2509 
 Pre-treatment Met + Asp  
4µM ADP -0.1985[-0.2835--0.9970] -0.9904[-0.9915--0.9715] 0.0579 
20µM ADP 0.02397[-0.1375-0.1628] -0.9903[-0.9937--0.9806] 0.0002 
Collagen 0.4084[0.3092-0.5472] -0.9748[-0.9881--0.9662] P<0.0001 
Arachidonic 
acid 
8.920[7.973-9.555] 1.848[1.061-2.227] P<0.0001 
 Pre-treatment Clopidogrel  
4µM ADP -0.3844[-0.3936--0.04524] -0.9893[-0.9906--0.9881] 0.0251 
20µM ADP -0.2498[-0.3202--0.1291] -0.9859[-0.9912--0.9832] 0.0053 
Collagen 0.4724[0.06032-0.6927] -0.9859[-0.9898--0.9771] 0.0165 
Arachidonic 
acid 
7.670[6.951-7.776] 1.323[0.9795-2.118] 0.0108 
p<0.05 represented in boldface; values represented as median [IQR]; Met + Asp: metformin and low-
dose aspirin dual therapy; ADP: adenosine diphosphate. 
5.4. Discussion 
The aim of the study was to investigate the effects of dual of metformin and low-dose aspirin therapy 
in modulating platelet function and reactivity in pre-diabetic mice. High-fat diet-induced pre-diabetes 
is used to study diabetes-associated complications (26). Previous studies have shown that the C57BL/6 
animal strain demonstrated thrombopoiesis mechanisms and antigen localization is analogous to 
humans (27). Although there was no significant difference in insulin levels or body weights, in our 
study the HFD-fed mice presented with delayed glucose clearance with no weight gain after 4-weeks 
on an HFD which is similar to findings by Toye et. al (28). Most importantly, the pre-diabetic mice 
showed abnormal platelet reactivity and function, an important pathophysiological sign in the 
development of thrombotic complications in pre-diabetes (29). Interestingly, treatment with dual 
therapy was effective in improving platelet function in our model. We highlight the synergistic function 
of metformin and aspirin in inhibiting platelet activation. Metformin improves the inhibitory function 
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of aspirin by lowering the platelet reactivity during dual therapy, which may prompt further 
investigation into the metformin mechanism of action on platelet function.  
Currently, various thrombo-inflammatory molecules that can be modulated by some drug targets such 
as P-selectin are continually investigated for their potential role platelet physiology (30). P-selectin, 
which is localized in the α-granules, is translocated to the surface of activated platelets where plays a 
role in stabilizing platelet aggregates as well as their interaction with leukocytes (31,32). However, low-
dose aspirin had no effect on the expression of CD36 (glycoprotein IV) indicating possible platelet 
activation mediated by COX-independent pathways in pre-diabetes. Activation of the COX-pathways 
is dependent on an increase in calcium levels. This is a consequence of the binding of ADP, collagen 
and TXA2 to their respective receptors (33). Cyclooxygenase oxidises arachidonic acid converting it 
into prostaglandins G2 and H2 leading to TxA2 production. This leads to the activation of platelet 
phospholipase C by the binding of TxA2 to the TxA2 receptor (TP) (34–36). We assume irreversible 
acetylation of cyclooxygenase by low-dose aspirin inhibits this process of conversion, resulting in 
decreased platelet activation and consequently decreased hypercoagulability (37,38). However, aspirin 
resistance has been reported in 41.9% of patients with T2DM (10). The failure of aspirin to inhibit 
platelet TxA2 production and other thromboembolic ischemic events is common in T2DM and may be 
attributed to high platelet turnover, as well as glycation and acetylation of platelet membrane proteins 
(39–41). In this current study, the purinergic receptor and GPVI mediated pathways were not inhibited 
in the low-dose aspirin group, which may result in high on-treatment platelet reactivity (HTPR). Similar 
findings were reported by Duzenli et. al (18), who demonstrated in a cohort of patients with T2DM that 
low-dose aspirin did not adequately inhibit ADP and collagen-induced platelet activation (18). 
However, the use of combination therapy consisting of low-dose aspirin and a P2Y12 receptor antagonist 
such as clopidogrel could offer partial and variable inhibition (42). This suggests that the combination 
of a well-known antidiabetic drug such as metformin could also reduce cardiovascular complications 
in people living with T2DM, although additional investigations are needed to establish the mechanisms 
involved (43).  
In our study, the use of metformin and low-dose aspirin as a dual therapy significantly reduced platelet 
activation and the exocytosis of P-selectin from the alpha granule, by altering the P2Y12 receptor, GPVI 
and the cyclooxygenase-dependent pathways. Furthermore, the use of metformin in combination with 
low-dose aspirin further inhibited the expression of CD36, a receptor that is known to be increased in 
diabetic and insulin-resistant patients. A study by Handberg et.al (44), showed an increased level of 
soluble CD36 in overt T2DM. Metformin, on the other hand, has been shown to enhance the effect of 
aspirin mediated cyclooxygenase inhibition by decreasing the levels of 11-dehydrothromboxane B2 
urinary excretion (13). This is agreement with a previous study by Formoso et. al (45), demonstrating 
reduced levels of urinary 11-dehydrothromboxane B2 in metformin-treated T2DM patients. In addition, 
metformin inhibits platelet activation, aggregation and decreases the mean platelet volume which is 
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associated with vascular complications in T2DM (46). Although our results support the use of 
metformin in combination a low-dose aspirin, the direct impact of this antidiabetic drug on platelets 
still remains unclear. However, it is suggested that metformin may inhibit platelet mitochondrial DNA 
release in platelets activated with either ADP, arachidonic acid or thrombin, leading to platelet 
aggregation (43). In our study, we observed reduced levels of platelet degranulation and the exocytosis 
of P-selectin in the response to post-treatment with metformin and low-dose aspirin. 
We further assessed platelet function following clopidogrel treatment, which is a known antagonist of 
the P2Y12 receptor that is activated in the liver by cytochrome P450 34A (17,19,47). The P2Y12 receptor 
antagonist reduced platelet degranulation and the exocytosis of P-selectin, leading to inhibition of both 
GPVI and P2Y12 pathways. However, residual platelet activation in response to activation of the 
cyclooxygenase pathway by arachidonic acid was observed. In addition, a variable dose-dependent 
response to ADP in the clopidogrel group was also observed, which may be due to the variability in the 
platelet response to endogenous agonists following clopidogrel treatment (17,48). An accelerated 
platelet turnover or single nucleotide polymorphism (SNPs) in the P2Y1 and P2Y12 receptors, as well as 
variations in surface density of the receptors,  may be responsible for the observed variability (17,49). 
This was a limitation to our study, however, clopidogrel dose used in this study significantly reduced 
the expression of CD36 which may indicate inhibition of platelet shape change caused by increased 
intracellular calcium levels (50). 
Platelet activation is orchestrated by multiple pathways that converge and result in morphological 
changes, degranulation and aggregation (51,52). In T2DM, there is increased platelet reactivity in 
response to endogenous agonists such as ADP, arachidonic acid and collagen (9). The complex nature 
of platelet signalling creates for a challenge in tailoring patient treatment options. Residual platelet 
activation during aspirin and clopidogrel treatment at the pre-diabetic stage may be useful in the 
thrombotic risk stratification of pre-diabetic individuals. In addition, resistance to both anti-platelet 
therapies has been reported in T2DM (17,49). The therapeutic targeting of these pathways plays a 
pivotal cardioprotective role and may reduce the risk of thrombotic complications (53). In our study, 
the combination therapy consisting of metformin and low-dose aspirin inhibited residual platelet 
activation in pre-diabetic mice. The high on-treatment platelet reactivity highlights the involvement of 
complex platelet signalling pathways and may suggest the importance of dual-therapy approach in 
preventing thrombotic complications in pre-diabetes. 
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Chapter 6. General discussion 
The project investigated platelet activation and function in pre-diabetes following treatment with anti-
inflammatory and anti-thrombotic drugs. We further assessed the association of PMAs as a possible 
link between the pro-thrombotic and pro-inflammatory condition reported in pre-diabetes. The effect of 
low-dose aspirin and clopidogrel as monotherapy were compared to the dual therapy consisting of 
metformin and low-dose aspirin. This was conducted to assess the levels of residual high on-treatment 
platelet reactivity (HTPR), that contributes to residual platelet activation associated with adverse 
cardiovascular disease (CVD) outcomes in type 2 diabetes mellitus (T2DM) (1, 2). Residual platelet 
reactivity has been reported in obese individuals (3) whereas we report on the presence of HTPR using 
a non-obese pre-diabetic mouse model. 
6.1. Increased platelet activation in pre-diabetes 
P-selectin is expressed on the membrane surface due to the degranulation of α-granules when platelets 
are activated (4). It binds to P-selectin glycoprotein ligand-1 (PSGL-1) on the surface of monocyte and 
neutrophils prompting a pro-inflammatory response thereby highlighting the role of platelets in the 
inflammatory process (4, 5). Platelet-monocyte aggregates (PMAs) are more robust markers for platelet 
activation and function which contribute to the increased thrombotic and pro-inflammatory 
environment in T2DM (6–8). Our study demonstrated comparable levels of PMA formation in the pre-
diabetic condition in post-stimulation with adenosine diphosphate (ADP). This highlights an important 
finding that in the pre-diabetic condition, platelets are already at their maximal activation state hence 
can bind to monocytes and other leukocytes to form aggregates. Platelet binding also increases the pro-
coagulant activity of monocytes with increased expression of tissue factor (9). Platelets from the pre-
diabetes group are hyperreactive and exhibit high affinity to monocyte binding giving rise to PMAs 
which are sensitive markers of in vivo platelet activation (10–12). An increase in the formation of PMAs 
is also regarded as an early marker for T2DM that occurs independently of inflammation (13). Our 
study was able to demonstrate the formation of PMA providing evidence of the interaction between 
inflammatory and thrombotic mechanisms at the pre-diabetic stage.  
6.2. Platelet function in pre-diabetes 
Platelet activation is mediated by various signalling pathways activated through the interaction of 
ligands and surface receptors which include, the purinergic receptor (P2Y12) (14), thromboxane A2 
receptor (TP) (15, 16) and collagen receptor (GPVI) (17). The common activation pathways involve 
receptor agonist binding on the platelet surface leading to the activation of phospholipase-Cγ (PLCγ), 
phospholipase-Cβ (PLCβ), phosphoinositide-3 kinase (PI3K) and adenyl cyclase. Activation of these 
receptors culminates in elevated calcium levels which play a role in shape change and secretion of 
platelet granules. The pathophysiology of platelet hyperreactivity in pre-diabetes and T2DM is well 
documented. Increase in platelet reactivity is attributed to glycation of the membrane proteins, increased 
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surface expression of P-selectin, increased intracellular calcium concentration, activation of protein 
kinase C (PKC) and increased cellular adhesion molecules (18). Metabolic changes which include 
impaired glucose metabolism contribute to increased platelet reactivity in T2DM (2, 19). In healthy 
individuals, acute hyperglycaemia results in the increased expression of P-selectin and CD40-ligand as 
well as activation of the PKC (2). Insulin deficiency, which was not exhibited by the pre-diabetic mice 
in this study, enhances the platelet response to collagen and ADP agonist (19). 
It is currently known that ADP is an endogenous agonist capable of reversible or irreversible platelet 
activation at varying concentrations (20). In our study, in the pre-diabetic group, platelets were 
hyperreactive to stimulation with ADP which resulted in dense and α granule release and consequently 
increased expression of P-selectin from the α-granules on the platelet surface (21). In this manner, 
stimulation of the P2Y12 receptor maintains and amplifies platelet activation, as well as stabilizes 
platelet aggregates (22, 23). In addition, the P2Y12 receptor plays a role in ADP mediated thromboxane 
A2 generation which in turn irreversibly activates the receptor itself (21). Cyclooxygenase plays a role 
in the metabolization of arachidonic acid into short-lived prostaglandins which are later converted to 
bioactive thromboxane A2, an activator of platelet aggregation (4, 24). In brief, cyclooxygenase 
transforms arachidonic acid into prostaglandin H2 which is transformed into prostaglandins and 
thromboxanes by synthases including cytosolic prostaglandin E synthase (cPGES), microsomal 
prostaglandin E synthase-1 (mPGES-1), prostaglandin I synthase (PGIS) and thromboxane synthase 
(TxS) (5). In our study, we demonstrated that stimulation of the cyclooxygenase pathway increased 
platelet reactivity in the pre-diabetic condition. Thromboxane A2 is a potent vasoconstrictor and induces 
platelet adhesion, shape change and aggregation which may contribute to vascular occlusion and the 
development of cardiovascular disorders (4). In the pre-diabetes group, platelets were hyperreactive to 
activation of the GPVI receptor post stimulation with collagen. Once collagen is bound to GPVI, 
enzyme phospholipase Cγ (PLCγ) is activated, which hydrolyzes the lipid phosphatidylinositol-4,5-
bisphosphate (PIP2) into DAG and IP3 (6). As a result, intracellular calcium levels are increased leading 
to shape change and granule secretion (7, 16). Increased PKC levels lead to the expression of the GP 
IIb/IIIa complex and consequently platelet aggregation via the binding of fibrinogen to its co-receptor 
(8). Increased fibrinogen binding, as well as expression of granule secreted P-selectin, have been 
demonstrated in hyperglycaemia and in diabetic patients with CVD (8, 9). 
6.3. High on-treatment platelet reactivity (HTPR) in pre-diabetes 
We assessed whether the use of clopidogrel, a P2Y receptor antagonist that blocks the binding of ADP 
(10), could inhibit residual platelet reactivity in pre-diabetes. Our study demonstrated the inhibition of 
the P2Y12 receptor-mediated platelet activation in clopidogrel-treated pre-diabetic mice. We further 
demonstrated the synergistic effect of metformin and low-dose aspirin dual therapy in inhibiting platelet 
activation and function. The combination of metformin and low-dose aspirin reduced platelet reactivity 
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in response to ADP stimulation compared to low-dose aspirin monotherapy. Low-dose aspirin 
monotherapy reduced platelet reactivity in pre-diabetic platelets stimulated with arachidonic acid 
providing evidence of its COX inhibitory function. Similarly, the addition of metformin to low-dose 
aspirin therapy also inhibited COX activation. Whereas in the clopidogrel-treated group, platelet 
hyperreactivity to arachidonic acid was observed in the pre-diabetic group. The continued platelet 
hyperreactivity despite clopidogrel treatment, illustrates that the calcium levels can still be elevated 
even after inhibition of the GPVI receptor. Therefore, the COX pathway is still activated due to 
increased calcium levels. Treatment with metformin and low-dose aspirin dual therapy reduces platelet 
hyperreactivity post stimulation with collagen, which was not observed following low-dose aspirin 
treatment. This may suggest the synergistic properties of dual therapy in pre-diabetes and a possible 
GPVI downstream inhibitory effect of metformin.  
Overall, the current study demonstrated increased platelet activation and function in pre-diabetes. We 
further highlight the interaction between monocytes and activated platelets. In addition, we 
demonstrated variable significant HTPR in the dual metformin and low-dose aspirin therapy, low-dose 
aspirin and clopidogrel monotherapy indicating residual platelet activity. Our findings provide evidence 
of interaction of pro-inflammatory and pro-coagulant mechanisms and the role of platelets in increasing 
the risk of CVD in as early as the pre-diabetes stage. We also highlighted the pathways involved in 
platelet activation in response to agonists, as well as the increased platelet hyperreactivity to 
endogenous agonists in pre-diabetes. Importantly, we demonstrate a variant platelet inhibitory response 
to anti-glycaemic and anti-platelet therapy. This further highlighted the variable inhibition of the PKC 
and COX-1 mediated pathways by the anti-platelet therapy giving rise to persistent HTPR. This may 
explain the occurrence of CVD in pre-diabetic and diabetic patients on either anti-glycaemic and anti-
platelet treatment (11–13). Further work is required to investigate the efficacy of the combination of 
anti-platelet therapy and anti-inflammatory treatment regimens in a CVD model. Prospective work will 
investigate other coagulation factors such as tissue factor involved in the progression of thrombotic 
conditions in pre-diabetes. The targeting of the scavenger receptor sCD36 may provide important 
therapeutic impact in reducing the hypercoagulable state in T2DM. Further molecular work targeted at 
inhibiting or overexpression of PKC, including modulation of calcium homeostasis in pre-diabetes is 
planned for future experiments.  
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